RJuro/neuro_patents · Datasets at Hugging Face

appln_id int64 7.41k 576M	appln_filing_date stringlengths 10 10	docdb_family_id int64 3.49M 82.2M	granted stringclasses 2 values	appln_abstract stringlengths 120 10k	appln_abstract_lg stringclasses 1 value	appln_title stringlengths 4 567	applt_coun stringlengths 4 289	invt_coun stringlengths 8 347	cpc stringlengths 11 1.62k	ipc sequence	__index_level_0__ int64 25 167k
4,849,713	2002-10-15	19,190,745	N	Use of cultured nerve stem cells originating in embryo stem cells in producing a remedy for dysmnesia. Thus, dysmnesia caused by Alzheimer~s disease, etc. can be treated.	en	REMEDY FOR DYSMNESIA	5220222_JP	16705059_JP,16802151_JP,16802153_JP,16802152_JP	A61K 35/12,A61P 25/00,A61P 25/28,C12N 5/0623,C12N2501/115,C12N2501/41,C12N2506/02	[ "C12N 5/0797", "C12N 5/0735", "A61K 35/30", "A61K 35/12", "C12N 5/07", "A61P 25/28", "A61K 35/48" ]	8,478
53,498,267	1985-11-04	9,291,831	Y	3,20-dione-11 beta -hydroxypregn-4-ene-21-thioacetate-17-butyrate and 3,20-dione-11 beta -hydroxypregn-4-ene-21-thiopropionate-17-butyrate, are anti-inflammatory agents.	en	Hydrocortisone 17-oxo-21-thioesters and their uses as medicaments	9988226_FR	5907728_FR,5907725_FR,5907726_FR,5907724_FR,5907727_FR	A61P 29/00,C07J 31/006	[ "C07J 31/00", "A61K 31/57", "A61P 29/00", "C07J 5/00" ]	46,233
16,519,325	1983-07-05	23,563,694	N	14-Fluoromorphinans such as 17-cyclopropylmethyl-4,5-epoxy-14-fluoro-3-hydroxymorphinan-6-one are useful as analgesics, narcotic antagonists, and/or anorexigenic agents.	en	Analgesic, antagonist, and/or anorectic 14-fluoromorphinans.	11691_US	2372110_US	A61P 3/04,A61P 25/04,A61P 25/30,C07D 489/06,C07D 489/08	[ "A61P 25/30", "A61K 31/485", "C07D 491/20", "C07D 489/08", "C07D 489/06", "A61P 25/04", "A61P 3/04" ]	17,314
408,622,029	2013-02-14	40,156,919	Y	The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycatioπ endproducts receptor (RAGE).	en	Methods of treatment using rage fusion proteins	12455287_US	5606230_US,9649388_US	A61K 38/00,A61K 39/39533,A61P 3/00,A61P 3/10,A61P 11/00,A61P 13/12,A61P 17/00,A61P 19/02,A61P 25/00,A61P 25/28,A61P 27/02,A61P 29/00,A61P 37/00,A61P 37/06,A61P 43/00,C07K 14/70503,C07K 19/00,C07K2319/30	[ "C07K 14/705", "A61K 39/395", "A61K 38/00" ]	80,909
51,074,423	1995-06-05	10,761,188	Y	This invention provides novel, optionally substituted tetrahydropyridoindoles which are useful serotonergic agents for the treatment of central nervous system disorders.	en	Serotonerbic tetrahydropyridoindoles	5255150_US	8264853_GB,5385049_GB,5385050_GB,6157413_GB,5385051_GB	C07D 471/04	[ "C07D 471/04" ]	41,207
502,832,134	2018-05-10	64,097,855	N	The components and structure for a genome created for the purpose of the evolutionary development of artificial intelligence systems/machines without human intervention.	en	Genome and self-evolution of AI	55946744_GB	55946744_GB	C12Q 1/6869,G06N 3/008,G06N 3/086,G06N 3/123,G06N 3/126,G06N 20/00,G16B 5/00,G16B 20/00,G16B 20/20,G16B 20/50,G16B 25/00,G16B 30/00,G16B 40/00,G16B 50/00	[ "G06N 3/12", "G06F 19/22", "G06F 19/24", "G06N 3/08", "G06F 19/20", "G06F 19/28", "G06F 19/12", "G06F 19/18" ]	122,504
379,372,671	2012-06-22	47,362,494	N	A method and apparatus including a mobile device for administering and quantitatively determining a Risk Index that a user has suffered an impairment of brain function.	en	METHOD AND APPARATUS FOR MULTIMODAL MOBILE SCREENING TO QUANTITATIVELY DETECT BRAIN FUNCTION IMPAIRMENT	12289371_US,11078540_US,12289370_US,12289369_US	12289370_US,12289371_US,12289369_US	A61B 5/1124,A61B 5/162,A61B 5/163,A61B 5/378,A61B 5/4023,A61B 5/6898,A61B 5/7275,G16H 10/20,G16H 50/30	[ "A61B 5/11", "A61B 5/0484", "A61B 3/113" ]	77,607
340,704,440	2010-05-20	42,562,780	Y	The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[	en	Modulators of 5-HT receptors and methods of use thereof	42601377_US,44136250_DE	16145925_,43361876_,43379696_,15019348_,15019350_,16162056_,37001291_,43379698_,37070407_,43379700_,43379695_,43379697_,43379694_,43379699_,40629277_	A61P 1/04,A61P 1/14,A61P 3/04,A61P 3/10,A61P 9/00,A61P 13/10,A61P 15/10,A61P 17/06,A61P 25/00,A61P 25/04,A61P 25/06,A61P 25/08,A61P 25/16,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/30,A61P 25/34,A61P 25/36,A61P 27/02,A61P 43/00,C07D 471/14,C07D 487/04,C07D 491/04,C07D 491/044,C07D 491/056,C07D 491/147,C07D 495/04,C07D 495/14,C07D 495/16,C07D 513/04	[ "A61K 31/551", "A61K 31/554", "A61P 25/00", "A61K 31/553", "C07D 495/04", "C07D 487/04", "C07D 491/04" ]	71,708
379,362,779	2010-11-19	44,991,967	Y	The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[	en	Modulators of 5-HT receptors and methods of use thereof	44136250_DE,42601377_US	40629277_,43379695_,43379700_,43379697_,43379694_,16145925_,43379696_,43361876_,37070407_,15019348_,15019350_,43379698_,37001291_,16162056_,43379699_	A61K 31/55,A61P 1/00,A61P 1/04,A61P 1/14,A61P 3/00,A61P 3/04,A61P 3/10,A61P 9/12,A61P 13/10,A61P 15/00,A61P 15/10,A61P 17/06,A61P 19/08,A61P 25/00,A61P 25/04,A61P 25/06,A61P 25/08,A61P 25/14,A61P 25/16,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/30,A61P 25/34,A61P 27/02,A61P 27/06,A61P 29/00,A61P 43/00,C07B2200/13,C07D 209/94,C07D 471/14,C07D 487/04,C07D 491/04,C07D 491/044,C07D 491/147,C07D 495/04,C07D 495/14,C07D 513/04	[ "A61K 31/55", "A01N 43/46", "A01N 43/00" ]	77,572
405,387,702	2012-10-05	48,042,509	N	The present invention provides methods and systems for assessing cognitive function by comparing a subject's eye movements within and across distinct classes of images.	en	METHODS AND SYSTEMS FOR ASSESSING COGNITIVE FUNCTION	12373545_CA,10257084_CA	12373545_CA	A61B 3/032,A61B 3/113,A61B 5/163,A61B 5/165,A61B 5/4884,G16H 40/63,G16H 50/30	[ "A61B 3/032", "A61B 6/00" ]	79,235
55,856,128	2001-04-20	24,224,775	Y	13. A computer-readable medium comprising instructions that upon execution in a processor cause the processor to perform the methods as recited in any of claims 5 to 8.	en	Predictive dequantization of voiced speech	21051_US	30136_US,939523_US,49516734_IN,714758_US,49680237_US	G10L 19/0204,G10L 19/032,G10L 19/04,G10L 19/08,G10L 19/097,G10L 19/26,G10L 25/12	[ "G10L 25/90", "G10L 19/14", "H03M 7/36", "G10L 11/00", "G10L 19/08", "G10L 19/04", "G10L 19/02" ]	54,093
413,028,541	2013-05-29	49,671,097	N	A method of treating a patient with an ailment, comprises delivering ultrasound energy to a dorsal root ganglia (DRG), thereby modulating the DRG to treat the ailment.	en	ULTRASONIC MEANS AND METHODS FOR DORSAL ROOT GANGLION NEUROMODULATION	5344841_US	11403098_US,5230409_US	A61N 7/00,A61N 7/022,A61N2007/003,A61N2007/0078	[ "A61N 7/00" ]	83,600
267,301,114	2009-03-11	41,065,523	N	Provided are methods for treatment and prophylaxis of convulsive disorders and seizures, such as epilepsy and febrile seizures, by modulating TRPVl channel activation.	en	TREATMENT AND PROPHYLAXIS OF EPILEPSY AND FEBRILE SEIZURES	12540094_US,41002278_US,41002275_US,41002276_US,41002277_US	41002275_US,41002276_US,41002278_US,41002277_US	A61K 31/44,A61K 31/55,A61P 25/00,A61P 25/08	[ "A61K 31/55", "A61K 31/44", "A01N 43/56" ]	57,857
53,816,318	2001-05-10	27,807,159	N	Novel mammalian Zneu1 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.	en	Mammalian neuro-growth factor like protein	8217604_US	29519879_US,18458773_US	A61K 48/00,C07K 14/475,C07K2319/00	[ "C07K 14/475", "A61K 48/00" ]	47,204
329,267,118	2009-09-08	40,863,048	N	Subject matter disclosed herein may relate to a biometric security technique, and may relate to biometric identity verification and emotional stress state evaluation.	en	BIOMETRIC IDENTIFY VERIFICATION INCLUDING STRESS STATE EVALUATION	11590846_GB,11590847_GB,11590845_GB,5895541_GB	11590846_GB,11590847_GB,11590845_GB	C04B 41/009,C04B 41/4922,C04B 41/84,C04B2111/00965	[ "G05B 19/00" ]	65,163
335,684,469	2011-07-07	44,584,801	N	Certain embodiments of the present disclosure support techniques for power efficient implementation of neuron synapses with positive and/or negative synaptic weights.	en	METHODS AND SYSTEMS FOR CMOS IMPLEMENTATION OF NEURON SYNAPSE	12605958_US,12988305_US,5818520_US	12605958_US,12988305_US	G06N 3/049,G06N 3/0635,G11C 11/54	[ "G06N 3/063" ]	68,599
57,646,035	2008-10-14	40,753,767	Y	The present invention relates, in general, to perioperative depression and, in particular, to methods of identifying individuals at risk of perioperative depression.	en	Predictors of long-term mortality following coronary artery bypass graft surgery	10706874_US,10706871_US,10706870_US,10706876_US,5219375_US,11032243_US,11032244_US	10706870_US,11032244_US,10706876_US,10706874_US,10706871_US,11032243_US	C12Q 1/6883,C12Q2600/106,C12Q2600/156	[ "C12P 19/34", "C12Q 1/68" ]	56,490
524,926,015	2019-07-11	69,142,677	N	The present invention provides a method for promoting the functional maturation of a neural network by culturing neurons on a fiber sheet serving as a cell scaffold.	en	METHOD FOR FUNCTIONAL MATURATION OF NEURONS	74012124_JP,68510194_JP	73966571_JP,71195635_JP,71178089_JP,74392205_JP	C12Q 1/02	[ "C12N 5/0793", "C12N 5/0797", "C12Q 1/02" ]	136,065
51,813,794	2006-11-09	38,004,224	Y	The invention generally provides a biomarker for sleepiness, a method for detecting sleepiness, and a method of identifying nucleic acids associated with sleepiness.	en	Methods for detecting sleepiness	8829302_US,8829300_US,8829303_US,8829301_US,5348505_US	8829300_US,8829303_US,8829301_US,8829302_US	C12Q 1/40,C12Q 1/6883,C12Q2600/158,G01N2800/2864	[ "C12Q 1/40" ]	42,846
54,022,907	1992-06-04	15,697,565	Y	Antiferroelectric liquid crystal composition comprising at least one of antiferroelectric liquid crystal substances, and at least one of optically active substances.	en	Liquid crystal composition	5437228_JP	5302889_JP,5625441_JP,5493379_JP	C09K 19/0266,C09K 19/2021,C09K 19/586	[ "C09K 19/20", "C09K 19/54", "G02F 1/13", "C09K 19/02", "C09K 19/58" ]	47,872
267,456,895	2009-03-24	41,114,625	N	Materials and methods for identifying human natural anti-Aß autoantibodies, as well as materials and methods for using such antibodies to treat Alzheimer's disease.	en	HUMAN MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN, AND THEIR USE AS THERAPEUTIC AGENTS	36976054_US,5547498_US,41039785_US,13475849_US,41039784_US	41039785_US,41039784_US,13475849_US,36976054_US	A61P 25/28,C07K 16/18,C07K2317/21	[ "A61K 39/395", "A61P 25/28" ]	58,043
561,409,392	2021-05-19	78,608,184	N	Various embodiments of a system and associated method for determining a social structure in unstructured and/or structured social media forums are disclosed herein.	en	SYSTEMS AND METHODS FOR SOCIAL STRUCTURE CONSTRUCTION OF FORUMS USING INTERACTION COHERENCE	74795249_US,72422302_US,81899581_US,48323488_US	72422302_US,81899581_US	G06F 16/31,G06F 16/358,G06F 16/36,G06N 3/0454,G06N 3/08,G06N 20/00	[ "G06F 16/31", "G06N 20/00" ]	160,296
53,168,972	2003-12-23	34,108,383	N	A contrast card comprising at least two colored zones corresponding respectively to the average color of at least two regions of the face of a panel of individuals.	en	Cosmetic compositions and contrast cards for characterizing them	5317775_FR	39469056_FR,39469057_FR,22167461_FR	A45D 44/005,A45D2044/007,A61K 8/02,A61K 8/11,A61K 8/894,A61K2800/412,A61Q 1/02	[ "A61K 8/02", "A45D 44/00", "A61Q 1/02", "A61K 8/11", "A61K 8/894" ]	45,474
26,511,114	1976-03-16	26,249,900	Y	PURPOSE:A drug for improving and treating clouding of consciousness caused by head injury, cerebral operation, blood vessel lesion in brain, or cerebral tumor etc.	en	A DRUG FOR IMPROVING AND TREATING CLOUDING OF CONSCIOUSNESS	13636911_	30775800_,19703529_	A61K 38/066,A61P 25/28	[ "A61K 38/04", "A61K 38/06", "A61P 25/28" ]	24,413
4,757,935	2000-10-26	22,580,950	N	Polynucleotides, polypeptides, kits and methods are provided related to gene s expressed in the central nervous system that are regulated by neuroleptics.< /SDOAB>	en	REGULATION OF GENE EXPRESSION BY NEUROLEPTIC AGENTS	16674967_US	16582525_US,16700156_US,13455256_US,16713114_US,16713115_US	A61P 25/18,C07K 14/47	[ "C12N 1/15", "A61K 38/00", "C12Q 1/68", "C12N 15/09", "C12N 1/19", "C12N 5/10", "C12N 1/21", "C12P 21/08", "C07K 16/18", "A61K 39/395", "C07K 14/47", "A61P 25/18" ]	7,288
274,456,153	2008-01-31	41,608,921	N	Methods and apparatus for deriving a response time to a challenge in a network, and to a knowledge based quiz game suitable for use with the methods and apparatus.	en	Response time derivation and game	8867732_GB,11273709_GB,11273708_GB	8867732_GB,11273709_GB	G07F 17/32,G07F 17/3288,G07F 17/3295,H04L 63/0428,H04L2463/041	[ "A63F 13/00", "A63F 9/24" ]	60,217
554,801,430	2020-03-31	70,457,118	N	The present disclosure generally relates to activity trends and exercise, and more specifically to techniques for presenting activity trends and managing workouts.	en	Activity trends and workouts	58240756_	59040164_,59352766_,80256136_,64938449_,71350441_,58709090_,79875817_,75474505_,79841435_	A61B 5/112,A61B 5/1124,G06F 3/0483,G06F 3/04883,G06F 9/451,G16H 20/30,G16Y 10/65,G16Y 20/40,G16Y 40/10	[ "G06F 3/0483", "G06F 3/0488", "G06F 9/451", "G16Y 10/65", "G16Y 40/10", "G16Y 20/40" ]	155,981
559,321,269	2021-04-07	78,023,688	Y	A method of determining structured behavior from network adjacency matrices is described. A method of detecting physiological signals from a subject is described.	en	Method for uncovering deeply hidden enzyme-like behaviors from physiological time-series measures for disease detection, monitoring and other applications	81840442_US,56948003_US	56907649_US,56893160_US,6040234_US	A61B 5/0095,A61B 5/14542,A61B 5/14551,A61B 5/4064,A61B 5/4312,A61B 5/441,A61B 5/7246	[ "A61B 5/145" ]	159,038
53,909,756	2007-10-10	39,676,716	Y	This invention provides compounds of formula A and formula B which are modulators of potassium ion channels and are useful for the treatment of seizure disorders.	en	N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators	45164958_US,7385380_US,6341105_US,10300027_US,7629018_US	10300027_US,6341105_US,7629018_US,7385380_US	C07C 233/43,C07C 233/44,C07C 235/16,C07C 235/24,C07C 271/28	[ "A61K 31/167", "A61K 31/27", "C07C 271/28", "C07C 239/00", "C07C 237/00", "C07C 235/00", "C07C 233/00", "C07C 233/25" ]	47,509
48,885,447	1981-02-17	26,758,323	Y	The synthesis, resolution, radiolabeling and determination of the superior immunoreactivity of the syn isomer of a derivative of cortisol-21-acetate is described.	en	Preferential immunoreactivity of syn-isomer of cortisol derivative	5258882_US	7039233_US,5714211_US	C07J 41/0016	[ "C07J 41/00" ]	37,907
4,177,509	1983-02-10	23,392,697	Y	Title Antiinflammatory and/or Analgesic 2,3-Diaryl-5-Halo Thiophenes Certain 2,3-diaryl-5-halo thiophenes are useful in the treatment of inflammation and/or pain.	en	ANTIINFLAMMATORY AND/OR ANALGESIC 2,3-DIARYL-5-HALO THIOPHENES	15817366_	16091470_	A61P 25/04,A61P 29/00,C07D 333/28,C07D 409/04	[ "C07D 409/04", "A61K 31/44", "A61K 31/381", "C07D 333/28", "A61K 31/38", "A61P 29/00", "A61P 25/04", "A61K 31/4433" ]	3,487
48,727,963	1980-12-12	26,754,909	Y	Neuroleptically active octahydro-1H-pyrrolo[2,3-g]isoquinolines of the formula <IMAGE> A wherein R1, R2, R3, R4 and X are as hereinafter set forth, are described.	en	Octahydro-2-methyl-isoquinoline-6,8-dione	5244394_US	5278373_US,5259436_US	C07D 209/08,C07D 217/04,C07D 471/04	[ "C07D 209/08", "C07D 471/04", "C07D 217/04" ]	37,673
29,496	2008-01-04	39,594,365	N	We present a novel design for an optical differential quadrature phase shift keying modulator comprised of two intensity modulators in a three-arm interferometer.	en	COMPACT OPTICAL MODULATOR	12490364_US,5273833_US	12490364_US	H04B 10/505,H04B 10/5561	[ "H04B 10/155" ]	109
4,758,016	2000-10-26	22,586,846	N	Novel 5-benzyl-octahydroindoles and 6-benzyl-decahydroquinolines substituted in the 1-position are effective as NMDA NR2B antagonists useful for relievin g pain.	en	5-BENZYL-OCTAHYDROINDOLE AND 6-BENZYL-DECAHYDROQUINOLINE NMDA/NR2B ANTAGONISTS	7460330_US	16596289_US,12705490_US,12488961_US	A61P 9/00,A61P 25/00,A61P 25/04,A61P 25/06,A61P 25/16,A61P 25/18,A61P 25/22,A61P 25/24,C07D 209/10,C07D 215/06,C07D 235/06	[ "A61P 25/04", "A61P 25/06", "A61P 25/00", "A61P 9/00", "A61P 25/22", "A61P 25/24", "C07D 209/10", "C07D 403/06", "C07D 209/08", "C07D 215/06", "C07D 235/06", "C07D 401/06", "A61P 25/18", "A61K 31/404", "A61P 25/16", "A61K 31/4184", "A61K 31/4709", "A61K 31/4178" ]	7,289
546,530,188	2020-08-25	74,684,531	N	The present invention provides genetic markers associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.	en	GENETIC VARIANTS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE	12489970_CN	44354467_CN,80733166_CN,41265035_CN,13167591_CN,57473192_CN,57436762_CN	A61K 31/496,A61K 45/06,A61P 25/28,C12Q 1/6883,C12Q2600/156,G01N 33/6896	[ "A61P 25/28", "A61K 31/496", "C12Q 1/68" ]	150,617
526,995,624	2018-05-02	58,709,424	N	The invention also provides the use of means for determining the amount of miR218-5p for predicting subject's responsiveness to a corticosteroid medical regimen.	en	PREDICTIVE RESPONSE BIOMARKERS TO CORTICOSTEROIDS	55847469_ES,48319979_ES	74641049_ES,74708921_ES,74720830_ES,74787723_ES	C12Q 1/6883,C12Q2600/178	[ "C12Q 1/6883" ]	137,313
381,253,848	2012-10-23	39,152,127	N	A cell line and an assay for discovering neurogenic drugs are described. The assay allows for systematic screening of test agents such as libraries of compounds.	en	METHOD FOR DISCOVERING NEUROGENIC AGENTS	7327797_US,7327797_US	5867952_US,5704995_US	G01N 33/5058	[ "C12N 5/0797", "G01N 33/53" ]	78,426
17,036,094	1994-04-09	22,014,118	Y	An asymmetrical hydroxyphenyl benzotriazolylphenol cpd. of formula (I) is new. In (I), R1 = methyl; R2 = octyl; and X = H, halogen, 1-12C alkyl, or 1-12C alkoxy.	en	Asymmetrical benzotriazolylphenols	554714_US	3319391_US,3319390_US	C07D 249/20	[ "C07D 249/20" ]	18,500
471,114,781	2016-07-14	49,989,665	Y	as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 4 (mGluR4) and/or altering glutamate level or glutamatergic signalling.	en	Substituted quinoxalines as positive allosteric modulators of mGluR4	5223450_DE	8382210_US	A61K 31/498,A61P 1/00,A61P 3/10,A61P 25/00,A61P 27/00,A61P 35/00,A61P 43/00,C07D 241/38,C07D 241/42,C07D 401/04,C07D 403/04	[ "C07D 241/36", "C07D 241/42", "C07D 241/38", "C07D 401/04", "A61K 31/498" ]	104,634
443,850,016	2015-02-20	53,882,484	N	The present disclosure relates to a system and method for generating survey questions, and to a system and method for managing behavioral health using the same.	en	SYSTEM AND METHOD FOR GENERATING SURVEY QUESTIONS	51515060_US	51532375_US,51492440_US,51569237_US,51463889_US,51418214_US	G16H 10/20,G16Z 99/00	[ "G06F 19/00" ]	95,392
440,698,470	2010-12-08	43,629,588	N	Disclosed is an antibody which binds to C4.4a comprising CDR sequences of FSNAWMSWV, VSYISSSGSTIYYADSVKGR, AREGLWAFDY, TGSSSNIGAGYVVH, DNNKRPS and CAAWDDRLNGPV.	en	Anti-c4.4a antibodies and uses thereof	15021570_	50298851_,39059210_,19716550_,44065192_,39457575_,44065191_,43906587_,44177493_,44177492_,44177494_,44177490_,44177491_	A61K 38/17,A61K 39/395,A61K 39/39558,A61K 47/42,A61K 48/00,A61K 49/16,A61K2039/505,A61P 35/00,A61P 35/04,C07K 14/435,C07K 14/475,C07K 16/18,C07K 16/22,C07K 16/28,C07K 16/30,C07K2317/21,C07K2317/33,C07K2317/55,C07K2317/56,C07K2317/565,C07K2317/73,C07K2317/732,C07K2317/77,C07K2317/92	[ "A61K 39/395", "C07K 16/30", "A61P 35/00", "G01N 33/53" ]	93,708
408,624,382	2013-03-01	48,744,381	N	A system for identifying the connectivity between different brain regions to determine the functional role of brain regions in various human and animal actions.	en	FUNCTIONAL EEG IMAGER	12456410_US,12138161_US,12138162_US	12456410_US,12138162_US	A61B 5/296,A61B 5/316,A61B 5/377,A61B 5/389,A61B 5/4064,A61B 5/4082,A61B 5/4244,A61B 5/6806,A61B 5/7203,A61B 5/742	[ "A61B 5/00", "A61B 5/0484", "A61B 5/04" ]	80,929
42,205,755	2001-03-30	20,279,146	N	A compound of formula I for use in therapy such as pain management, gastrointestinal disorders, spinal injuries or disorders of the sympathetic nervous system.	en	Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain	5465253_	13022271_,13022270_,13048877_	A61K 31/445,A61P 1/00,A61P 25/00,A61P 25/02,A61P 25/04,C07D 211/70,C07D 401/06,C07D 405/06,C07D 409/06,C07D 417/06	[ "A61P 25/00", "C07D 409/06", "A61K 31/4535", "A61K 31/4525", "A61P 1/00", "A61K 31/4545", "A61P 25/02", "C07D 405/06", "C07D 401/06", "A61P 25/04", "C07D 211/70", "C07D 211/68", "C07D 417/06", "A61K 31/4523", "A61K 31/4465" ]	28,178
11,080,239	1988-09-17	6,336,979	N	2-Carbamoyloxyphenyl phosphoro(di)thioate esters of formula (I) are new: R1 = 1-4C alkyl; R2 = H, 1-4C alkyl or 1-4C alkoxy; R3 = H or 1-4C alkyl; X = O or S.	en	O-(O-ETHYL-S-ALKYLPHOSPHORYL)-O-(CARBAMOYL)-BRENZKATECHINDERIVATE.	21465212_DE	22969277_DE,22969279_DE,22764122_DE,22848990_DE,22969278_DE	A01N 57/14,C07F 9/18	[ "A01N 57/14", "C07F 9/18" ]	11,103
525,255,352	2018-02-22	59,521,217	N	The invention further discloses a corresponding method for producing a cranial operculum for a living being, in particular implemented by means of a computer.	en	SYSTEM AND METHOD FOR PRODUCING A CRANIAL OPERCULUM FOR A LIVING BEING	72400901_IT	72306057_IT,72338306_IT,72296259_IT,72317735_IT	A61B 34/10,A61B2034/104,A61B2034/105,A61F 2/2875,A61F 2/30942,A61F2002/30578,A61F2002/30948,A61F2002/30952,A61F2002/30962,A61F2002/30985,B33Y 50/00,G05B 19/4097	[ "A61B 34/10", "B33Y 50/00", "A61F 2/28", "G05B 19/4097", "A61F 2/30" ]	136,373
48,848,306	1981-02-02	26,910,682	Y	Neuroleptically active cycloalka[4,5]pyrrolo[2,3-g]isoquinolines of the formula <IMAGE> A wherein n, R1, R2 and X are as hereinafter set forth, are described.	en	Cycloalka[4,5]pyrrolo[2,3-g]isoquinolines	5244394_US	5259436_US,5278373_US	C07D 209/88,C07D 217/04,C07D 471/04	[ "C07D 471/04", "C07D 217/04", "C07D 209/88" ]	37,841
509,128,988	2018-09-13	65,630,090	N	Provided herein are devices, systems, and methods, for capturing perioperative intracranial ultrasound images and for determining elasticity of brain tissue.	en	Ultrasound-Enabled Fiducials for Real-Time Detection of Brain Shift During Neurosurgery	52615275_US	69931167_CA	A61B 5/0042,A61B 5/031,A61B 5/4064,A61B 5/7267,A61B 8/0808,A61B 8/085,A61B 8/12,A61B 8/14,A61B 8/4444,A61B 8/463,A61B 8/481,A61B 8/485,A61B 8/488,A61B 8/5223,A61B 8/5246,A61B 8/5261,A61B 90/11,A61B 90/36,A61B 90/37,A61B 90/39,A61B2090/103,A61B2090/363,A61B2090/364,A61B2090/378,A61B2090/3925,A61B2090/3954,A61B2090/3966,A61B2090/3991,A61B2090/3995	[ "A61B 8/08", "A61B 90/00" ]	125,875
47,405,412	1998-10-23	22,046,368	N	Methods for specifically inactivating myelin proteins which inhibit nerve regeneration are described. These methods are useful to promote axon regeneration.	en	LASER INACTIVATION OF INHIBITORY MOLECULES IN CENTRAL NERVOUS SY STEM MYELIN	6104054_US,25604445_US	25604445_US	A61N 5/0601,A61N 5/062	[ "A61K 41/00", "A61N 5/06" ]	35,526
494,666,007	2017-11-20	62,145,857	N	The present invention relates to novel small molecule modulators of Nav1.6 channels of the general formulae (I), (II), (III) and (IV), and the uses thereof.	en	FINE-TUNE MODULATORS OF NEURONAL EXCITABILITY FOR NEUROPSYCHIATRIC DISORDERS	6893329_US	57696139_US,12327988_US,12618028_US,57396408_US	A61K 31/401,A61K 31/427,A61K 31/5377,A61K 38/1825,A61K 45/06,C07C 237/52,C07D 207/16,C07D 413/12,C07D 417/12,C07K 5/0808,C07K 5/0812,C07K 5/1016	[ "A61K 31/11", "C07D 207/00", "C07C 47/06", "C07C 47/02", "A61K 31/40", "A61K 31/401" ]	117,846
438,137,873	2014-09-09	37,806,954	Y	The invention provides methods of treating Friedreich's ataxia and other neurodegenerative or neuromuscular conditions using histone deacetylase inhibitors.	en	Treatment of friedreich's ataxia using histone deacetylase inhibitors	5258289_US	6251543_US,49874261_DE,9062919_US,9062920_US,6251544_US	A61J 1/00,A61K 31/167,A61P 25/00,A61P 25/14,A61P 25/28,C07C 225/10,C07C 231/00,C07C 231/02,C07C 233/07,C07C 233/25,C07C 233/29,C07C 233/43,C07C 233/44,C07D 213/75,C07D 215/38,C07D 215/40	[ "C07D 215/40", "A61J 1/00", "C07C 233/43", "C07C 233/25" ]	92,362
54,559,056	2005-07-25	35,733,672	N	An auditory theme represents at least one participant in a networked (102) group (104, 105, 106) interaction, and reflects an attribute of that participant.	en	THEMES INDICATIVE OF PARTICIPANTS IN PERSISTENT COMMUNICATION	6802822_US,6802824_US,6802821_US,39753230_US,5904088_US,39742245_US	39753230_US,6802822_US,6802821_US,39742245_US,6802824_US	G06F 3/165,G06Q 50/30,H04L 12/18,H04L 12/1813,H04L 51/043,H04L 65/403,H04L 67/131	[ "G06F 15/16" ]	50,476
317,678,739	2005-08-15	41,559,733	Y	A question and answer game includes more than one answer choice to each question and each answer choice has a strategic element with a risk/reward tradeoff.	en	Multiplayer game with strategic element	11451408_US,11260129_US,11451407_US	11260129_US,11451408_US	A63F 9/18,A63F 9/183,G07F 17/3276,G07F 17/3295	[ "A63F 1/00" ]	62,832
421,096,929	2013-12-05	39,588,961	Y	Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression.	en	Use of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid in treating symptoms associated with rett syndrome	8698530_FR,5219886_CH,11350507_CH,8944822_CH,12208728_CH,11350508_CH,8897738_CH,8944831_CH	8944831_CH,11350508_CH,8698530_FR,11350507_CH,8897738_CH,8944822_CH,12208728_CH	A61K 31/137,A61K 31/138,A61K 31/145,A61K 31/397,A61K 45/06,A61P 3/04,A61P 3/10,A61P 17/02,A61P 25/00,A61P 25/14,A61P 25/16,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 37/00,A61P 43/00	[ "A61K 31/137", "A61K 45/06", "A61K 31/397", "A61K 31/145", "A61K 31/138" ]	88,109
45,016,167	1998-08-18	27,369,092	Y	GABA analogs are useful to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome. Preferred treatments employ gabapentin or pregabalin.	en	Pharmaceutical composition for preventing and treating gastrointestinal damage and disorders, ethanol withdrawal syndrome, or pain	13071897_US,5355881_US	36715628_GB,16620941_US,36715627_CN,12700887_IT,36715629_US	A61K 31/195,A61K 31/197,A61K 31/40,A61K 31/405,A61K 31/42,A61K 31/54,A61K 31/60,A61K 45/06,A61P 1/00,A61P 1/04,A61P 25/32,A61P 29/00	[ "A61K 31/42", "A61K 45/06", "A61P 25/32", "A61K 31/405", "A61K 31/197", "A61K 31/40", "A61K 31/60", "A61K 31/195", "A61K 31/54", "A61P 1/04", "A61P 1/00" ]	28,975
227,090	2005-07-12	35,106,735	N	The invention relates to a method for the treatment of anorexia nervosa comprising the administration of a therapeutically effective amount of flibanserin.	en	USE OF FLIBANSERIN FOR THE TREATMENT OF ANOREXIA NERVOSA	142392_US	358913_US	A61K 31/496,A61P 1/14,A61P 25/24,A61P 43/00	[ "A61P 25/24", "A61K 31/496" ]	1,241
417,619,168	2014-01-14	36,889,233	N	The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus.	en	METHODS OF TREATING REFRACTORY REPETITIVE SEIZURES	5242161_DE	10805651_DE	A61K 9/0053,A61K 31/165,A61K 31/4015,A61K 31/55,A61K 31/5513,A61K 38/04,A61K 45/06,A61K2300/00,A61P 25/00,A61P 25/08,A61P 25/12,G01N 33/6893	[ "A61K 45/06", "A61K 31/165", "A61K 31/5513" ]	86,259
15,658,533	1991-07-31	6,411,708	Y	2-Phenyl-1,2-benzisoselenazol-3(2H)-one(Ebselen) is capable of reducing the cisplatin-induced nephrotoxicity and neurotoxicity during cytostatic treatment.	en	USE OF 2-PHENYL-1,2-BENZISOSELENAZOL-3(2H)-ONE	25618505_DE	25618506_NL,25618508_NL,25618511_NL,25618507_NL,25618510_NL,25618509_GB	A61K 31/41,A61K 33/243,A61P 35/00,A61P 43/00	[ "A61P 35/00", "A61K 33/24", "A61K 31/41", "A61K 31/28", "A61P 43/00", "C07D 293/06", "C07D 293/12" ]	12,201
4,241,385	1986-02-21	25,829,707	Y	The present invention relates to the combination of flupirtin and antichoilinergically aciting spasmolytics, having a synergistic effect at the same time.	en	COMBINATION OF FLUPIRTIN AND ANTICHOLINERGICALLY ACTING SPASMOLYTICS	12650811_	16144536_DE,16144534_DE,13093275_DE,16144535_DE,10333786_DE	A61K 31/44,A61K 31/46	[ "A61K 31/46", "A61K 31/44" ]	3,643
50,237,423	1970-05-06	21,879,676	Y	The acoustic impedance of the cornea is measured by comparing the energy it reflects with the energy reflected by a calibrated, variable impedance member.	en	MEANS AND METHOD FOR DETECTION OF GLAUCOMA	38685658_,13813512_	13813512_,38685658_	A61B 3/165,A61B 8/10	[ "A61B 8/10", "A61B 3/16" ]	39,752
338,131,277	2009-11-04	42,153,522	N	The present invention relates to techniques and systems for training a subject to modify his or her own neutronal activity within a selected brain region.	en	Drug-Enhanced Neurofeedback	11907425_US,5536866_US,11103405_US	11103405_US,11907425_US	A61B 5/055,A61B 5/375,A61B 5/486,A61B 6/037,A61K 31/197,A61K 31/198,A61K 31/42,A61K 45/06,A61P 25/00,G01N 33/9406,G01N2333/70571,G01R 33/4806,G09B 5/02,G09B 5/04,G09B 23/28	[ "A61P 25/00", "A61K 49/00", "G09B 19/00" ]	70,233
53,535,321	2001-03-07	26,883,189	Y	Methods relating to the use of neonatal animals to identify sleep wake states in the corresponding adults and/or phenotypically characterize such adults.	en	Analysis of muscular activity in neonatal animals to screen for mutations and/or drugs that alter sleep and wake states	5266690_US	10016249_US,10016248_US	A01K 29/00,A01K 29/005	[ "A01K 29/00" ]	46,336
54,422,530	2004-11-03	34,657,052	N	The present invention relates to the use of inhibitors of PACAP receptor activity for the treatment of pelvic floor pain syndrome and overactive bladder.	en	Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome	12502946_US	39667964_US,39667963_US	A61K2039/505,C07K 16/26,C07K 16/2869	[ "C07K 16/28", "C07K 16/26" ]	49,190
53,665,294	1986-02-03	25,577,460	Y	A peptide having the amino acid sequence Asp-Ser-Glu-Pro-Arg and capable of blocking immune complex binding to immunoglobulin Fc receptors is disclosed.	en	Immunotherapeutic antiallergic polypeptide agents which bind to basophil immunoglobin Fc receptors	7864128_US	10114364_US	A61K 38/00,C07K 16/065	[ "C07K 16/06", "A61K 38/00" ]	46,728
16,238,530	2005-03-24	34,993,449	N	A therapeutic and/or preventive agent for inner ear disorders comprising an IL-6 antagonist, preferably an anti-IL-6R antibody, as an active ingredient.	en	THERAPEUTIC AGENT FOR AURIS INTERNA DISORDER CONTAINING IL-6 ANTAGONIST AS ACTIVE INGREDIENT	50652_JP,6211_JP	1841634_JP,1841636_JP,1841635_JP,1841633_JP,226553_JP	A61K2039/505,A61P 19/08,A61P 25/02,A61P 27/16,A61P 29/00,A61P 31/12,A61P 35/00,A61P 43/00,C07K 16/2866	[ "A61P 27/16", "A61P 19/08", "A61P 25/02", "A61K 45/00", "C07K 16/28", "A61P 43/00", "A61P 31/12", "A61P 29/00", "A61P 35/00", "A61K 39/395" ]	16,183
518,106,589	2019-02-13	67,616,358	N	Methods are disclosed for treating inflammation and sepsis and for promoting thermoregulation by activating neurons expressing TRPA1 in the vagus nerve.	en	ACTIVATION OF TRPA1+ NOCICEPTORS IN THE VAGUS NERVE ATTENUATES SYSTEMIC INFLAMMATION	5224749_US	5224750_US,55887194_US,72432352_US	A61K 31/4439,A61K 41/0057,A61P 29/00,A61P 31/04	[ "A61K 31/4439", "A61P 29/00", "A61P 31/04", "A61K 41/00" ]	130,813
52,347,926	1984-07-12	27,069,019	Y	1-(2-Aryl-2-halo-1-ethenyl)-1_H-azoles having anticonvulsant properties which are particularly useful in the treatment of generalized forms of epilepsy.	en	1-(2-Aryl-2-halo-1-ethenyl)-1_H-azoles, and anticonvulsant use thereof	5223476_BE	5249841_BE	A61P 25/08,C07D 231/12,C07D 233/56,C07D 249/08	[ "C07D 521/00", "C07D 233/61", "C07D 333/00", "C07D 409/06", "C07D 249/08", "A61K 31/4164", "C07D 233/60", "C07D 233/56", "A61K 31/41", "A61K 31/415", "A61P 25/08", "A61K 31/4196" ]	43,890
530,427,680	2014-12-12	52,293,220	Y	Compound of formula (I), (I) pharmaceutical compositions on the basis thereof, and their usage for various disorders treatment including pain. Table: 9	en	PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS	9690471_US	9690471_US	A61K 31/675,A61K 31/685,A61K 45/06,A61P 1/00,A61P 1/02,A61P 1/06,A61P 9/06,A61P 11/14,A61P 13/00,A61P 13/02,A61P 19/00,A61P 19/02,A61P 21/00,A61P 25/00,A61P 25/02,A61P 25/04,A61P 29/00,A61P 43/00,C07D 213/18,C07F 9/576,C07F 9/58,C07F 9/59	[ "A61P 19/02", "C07F 9/576", "A61K 31/675" ]	139,738
52,477,830	1984-09-05	27,082,909	Y	This application relates to 4-amino-4,5-dihydro-2-thiophenecarboxylic acid, the C1-6 alkyl esters thereof and to their use in the treatment of epilepsy.	en	alpha -Aminobutyric acid transaminase inhibitors	5266511_US	6547115_US,9326132_US,6547114_US	C07D 333/38	[ "C07D 333/38" ]	44,124
53,587,949	2004-03-26	33,131,717	N	Disclosed are methods of identifying psychoactive agents, e.g., anti-depressant, anti-psychotic or opioid compound, using differential gene expression.	en	Psychoactive compound associated markers and method of use thereof	36937222_,39552690_,28909722_	36937245_US,39552691_US,36937246_US	C12Q 1/6883,C12Q2600/158,G01N 33/5008,G01N 33/5023,G01N 33/5058,G01N 33/94,G01N 33/9486	[ "C12Q 1/68", "G01N 33/94", "G01N 33/50", "G01N" ]	46,511
535,813,029	2020-02-04	71,836,700	N	The present disclosure relates to a mixed-reality therapy system is configured to provide tasks and prompts to a user and monitor the user's responses.	en	Mixed-Reality Autism Spectrum Disorder Therapy	74825685_US	74822355_US,74784410_US,74751715_US,74715034_US	A61M 21/00,A61M2021/005,A61M2205/3306,A61M2205/3375,A61M2205/3553,A61M2205/3584,A61M2205/3592,A61M2205/502,A61M2209/088,A61M2230/63,G06F 3/011,G06F 3/013,G06F 3/0482,G06F 3/0484,G06F 3/04842,G06F 3/147,G06F2203/011,G06V 40/174,G06V 40/18,G09G 5/37,G09G2340/12,G09G2354/00,G09G2380/08,G16H 20/70,G16H 40/67	[ "G06F 3/0484", "G09G 5/37", "G06K 9/00", "G16H 20/70", "G06F 3/01", "G16H 40/67", "A61M 21/00" ]	143,165
48,939,718	1981-03-09	26,839,413	Y	Octahydro-2H-pyrrolo[3,4-g]quinolines, useful as dopamine agonists, particularly as inhibitors of prolactin secretion and in treatment of Parkinsonism.	en	Octahydro-2H-pyrrolo[3,4,-g]quinolines	5255150_US	5259702_US,5259701_US	C07D 215/20,C07D 215/227,C07D 471/04	[ "C07D 215/20", "C07D 215/227", "C07D 215/22", "C07D 471/04" ]	38,002
48,118,712	1980-04-18	26,707,467	Y	Octahydro-2H-pyrrolo[3,4-g]quinolines, useful as dopamine agonists, particularly as inhibitors of prolactin secretion and in treatment of Parkinsonism.	en	Octahydro-2H-pyrrolo[3,4-g]quinolines	5255150_US	5259702_US,5259701_US	C07D 215/20,C07D 215/227,C07D 471/04	[ "C07D 215/227", "C07D 215/22", "C07D 471/04", "C07D 215/20" ]	36,699
51,874,851	1975-04-08	27,003,116	Y	Certain 4a-aryl-trans-decahydroisoquinolines are useful as analgesics. Exemplary is N-cyclopropylmethyl-4a-m-hydroxyphenyl-trans-decahydroisoquinoline.	en	4a-Aryl-trans-decahydroisoquinolines	5404506_US	6332377_US,7160045_US	C07D 217/02,C07D 217/04,C07D 217/16,C07D 217/24,C07D 317/62	[ "C07D 217/02", "C07D 217/04", "C07D 217/16", "C07D 317/62", "C07D 217/24" ]	42,963
416,628,802	2013-09-17	46,851,875	Y	Denne opfindelse angår reagenser samt reagenser til anvendelse i behandling, diagnosticering og sporing af sygdomme i forbindelse med lakse-alphavirus.	en	Fiskevaccine	52231432_CH	51905862_GB,51814361_CA	A61K 39/12,A61K2039/53,A61K2039/552,A61K2039/55566,C07K 14/005,C12N 7/00,C12N2770/36122,C12N2770/36134	[ "C07K 14/18", "A61K 39/12" ]	85,580
339,405,687	2009-04-27	41,255,710	N	Disclosed are methods for diagnosing AMD or a susceptibility for AMD by identifying one or more markers associated with peripheral retinal phenotypes.	en	Polynucleotides Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risks	5219722_US,10979441_US,5867956_US,6327013_US	10979441_US,5867956_US	C12Q 1/6883,C12Q2600/172	[ "C40B 30/04" ]	70,916
500,783,133	2018-06-01	63,670,424	Y	The present invention provides a method for clinically identifying Parkinson disease with normal cognition or Parkinson disease dementia in a subject.	en	Method for discriminating Parkinson's disease dementia from Parkinson's disease with normal cognition	48378190_TW	50041614_TW	B82Y 5/00,B82Y 25/00,G01N 33/5005,G01N 33/54326,G01N 33/6896,G01N2800/2835,G16B 20/00,G16H 50/20,H01F 1/0054,H01F 1/344	[ "G01N 33/50", "H01F 1/34", "G01N 33/543", "G01N 33/68" ]	121,285
336,623,704	2011-02-25	44,505,484	N	The present invention provides diagnostic and disease progression or recurrence prediction methods based on osteopontin levels in a biological sample.	en	Asbestos Exposure, Pleural Mesothelioma and Osteopontin Levels	5726689_US,11854225_US,5283479_US,11854226_US	11854226_US,11854225_US	G01N 33/57423,G01N 33/57488,G01N2333/52,G01N2800/56	[ "G01N 33/566" ]	69,297
54,390,075	1978-12-22	6,027,555	Y	Estradiol valerate has been discovered to possess neuropsychotropic activity, e.g., it is an effective anti-depressant having advantageous properties.	en	Use of estradiol valerate as an anti-depressant	5244541_DE	6028648_US,9206509_DE,10685466_DE	A61K 31/565,C07J 1/0074	[ "C07J 1/00", "A61K 31/565" ]	49,034
339,622,484	2011-08-04	45,065,201	N	A system and method for assessing engagement activities and influence using consumer-specific promotions in a social network environment is provided.	en	Assessing engagement and influence using consumer-specific promotions in social networks	11768456_US,11768457_US,11227980_US,8272137_US	11227980_US,11768457_US,11768456_US,8272137_US	G06Q 30/02,G06Q 30/0211	[ "G06Q 30/00" ]	71,043
422,250,595	2014-03-14	51,581,757	N	Compositions and methods for the identification of agents useful for the treatment of neurological disorders, including schizophrenia, are provided.	en	SCHIZOPHRENIA-ASSOCIATED GENETIC LOCI IDENTIFIED IN GENOME WIDE ASSOCIATION STUDIES AND USE THEREOF AS NOVEL THERAPEUTIC TARGETS	12476372_US	12592816_US,49022414_US	A61P 25/00,C12Q 1/6883,C12Q2600/106,C12Q2600/156,G01N 33/5008,G01N 33/6803,G01N2500/04,G01N2500/10,G01N2800/30,G01N2800/302,G01N2800/304	[ "C40B 30/04", "G01N 33/53", "A61P 25/00" ]	89,070
52,641,461	1984-11-09	27,036,145	Y	Compounds of the class of loweralkyl N-[amino(arylaminocarbonyl)iminomethyl]-N-methylglycinate acid addition salts are useful as antianxiety agents.	en	Anxiety alleviating compositions containing loweralkyl-N-[amino(arylaminocarbonyl)-iminomethyl]-N-methylglycinates	5248635_US	5395478_US	A61K 31/24	[ "A61K 31/24" ]	44,432
51,635,923	2000-03-24	26,824,079	Y	A method of treating an obsessive-compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual.	en	Methods of treating obsessive-compulsive spectrum disorders	5297847_US	8676220_US,8676221_US,8676222_US	A61K 31/135,A61K 31/15,A61K 31/4525,A61K 31/55	[ "A61K 31/4525", "A61K 31/15", "A61K 31/55", "A61K 31/135" ]	42,496
378,959,309	2012-03-01	46,798,708	N	This invention provides gene expression profiles useful for diagnosing lacunar stroke and for distinguishing lacunar stroke from non-lacunar stroke.	en	BIOMARKERS FOR THE DIAGNOSIS OF LACUNAR STROKE	11471308_US,11981845_US,5211659_US	11981845_US,11471308_US	C12Q 1/6883,C12Q2600/112,C12Q2600/158,C40B 40/06,G01N 33/6893,G01N2800/2871	[ "C40B 40/06", "C40B 30/04" ]	77,366
42,197,359	1999-06-18	22,231,857	N	A GABA analog and decongestant combination is used to treat sinus headache and sinus pain. The GABA analog can be either gabapentin or pregabalin.	en	Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain	6603839_	33973472_,33973473_	A61K 31/195,A61P 25/04,A61P 29/00,A61P 29/02,A61P 43/00	[ "A61K 31/195", "A61P 43/00", "A61P 25/04", "A61K 31/197" ]	27,996
52,049,704	2005-02-17	34,910,765	N	The invention provides methods and compositions for treating anxiety and fear disorders through inhibition of alpha-2,8-sialyltransferase activity.	en	Anxiolytic treatment by inhibition of a polysialyltransferase	9028049_US,9028050_US	9028051_US,6040561_US	A61K 31/00,A61K 31/715,G01N 33/6896,G01N2333/91148,G01N2500/04,G01N2800/301	[ "A61K 31/715" ]	43,337
352,824,421	2001-04-26	27,072,208	Y	COMPOUNDS OF FORMULA I(I)@PHARMACEUTICAL COMPOSITIONS OF THESE COMPOUNDS, AND USE OF SAID COMPOSITIONS TO CONTROL SYNAPTIC TRANSMISSION IN MAMMALS.	en	DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS	5634013_US	42864605_US,34162388_US,34148106_US,34148107_US,34148108_US,34148103_US,34145556_US,33569142_US,34148102_US	A61P 1/00,A61P 13/00,A61P 15/10,A61P 25/00,A61P 25/04,A61P 25/06,A61P 25/08,A61P 25/14,A61P 25/16,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/34,C07D 471/04,C07D 487/04	[ "A61K 31/4545", "A61P 25/16", "A61P 25/24", "A61K 31/454", "C07D 231/54", "C07D 487/04", "C07D 471/04", "A61P 25/34", "A61P 25/00", "A61P 25/14", "A61P 25/04", "A61P 25/18", "A61P 25/28" ]	73,020
378,944,191	2012-11-09	47,428,966	N	Certain aspects of the present disclosure support techniques for unsupervised neural replay, learning refinement, association and memory transfer.	en	METHODS AND APPARATUS FOR UNSUPERVISED NEURAL REPLAY, LEARNING REFINEMENT, ASSOCIATION AND MEMORY TRANSFER: NEURAL ASSOCIATIVE LEARNING, PATTERN COMPLETION, SEPARATION, GENERALIZATION AND HIERARCHICAL REPLAY	5818520_US	41923840_US,43867151_US	G06N 3/04,G06N 3/049,G06N 3/08	[ "G06N 3/04" ]	77,343
378,715,914	2012-11-09	47,295,178	N	Certain aspects of the present disclosure support techniques for unsupervised neural replay, learning refinement, association and memory transfer.	en	METHODS AND APPARATUS FOR UNSUPERVISED NEURAL REPLAY, LEARNING REFINEMENT, ASSOCIATION AND MEMORY TRANSFER: NEURAL COMPONENT MEMORY TRANSFER	5818520_US	41923840_US,43867151_US	G06N 3/04,G06N 3/0409,G06N 3/049,G06N 3/08,G06N 3/082	[ "G06N 3/08", "G06N 3/04" ]	77,191
378,622,216	2012-11-09	47,428,967	N	Certain aspects of the present disclosure support techniques for unsupervised neural replay, learning refinement, association and memory transfer.	en	METHODS AND APPARATUS FOR UNSUPERVISED NEURAL REPLAY, LEARNING REFINEMENT, ASSOCIATION AND MEMORY TRANSFER: NEURAL COMPONENT REPLAY	5818520_US	43867151_US,41923840_US	G06N 3/04,G06N 3/049,G06N 3/08,G06N 3/082	[ "G06N 3/08", "G06N 3/04" ]	77,120
52,980,683	1991-06-17	27,060,106	Y	A dosage form is disclosed comprising an anti-Parkinson's disease drug for administering to a patient in need of anti-Parkinson's disease therapy.	en	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement	5242357_US	5591736_US,5591737_US,5343375_US,5606318_US	A61K 9/0004	[ "A61K 9/26", "A61K 9/22", "A61K 9/00" ]	45,056
54,381,328	2008-01-08	39,641,625	N	Genes associated with schizophrenia are identified. Methods of screening small molecule compounds for use in treating schizophrenia are described.	en	GENES ASSOCIATED WITH SCHIZOPHRENIA	5223287_US	10679121_US,10679122_US,5838686_US	C12Q 1/6883,C12Q2600/136,C12Q2600/156,C12Q2600/16	[ "C12Q 1/68" ]	48,994
49,723,345	1973-03-02	19,815,125	Y	The invention relates to certain psychopharmacological peptides with the formula: A-L-Glu(X)-L-His-L-Phe-L-Arg(or L-Lys)-Y in which A represents:	en	PSYCHOPHARMACOLOGICALLY ACTIVE TETRA-, PENTA-, HEXA-, AND HEPTAPEPTIDES	20859138_	34926652_	A61K 38/00,C07K 14/695,C07K 14/6955	[ "A61K 38/00", "C07K 14/695" ]	39,264
554,298,997	2020-12-18	76,858,169	N	Disclosed herein include systems, methods, devices, and computer readable media for constructing a neural network by growing and self-organizing.	en	SELF ORGANIZATION OF NEUROMORPHIC MACHINE LEARNING ARCHITECTURES	5211760_US	79655245_US,79657723_US,79701923_US	G06N 3/049,G06N 3/08	[ "G06N 3/04", "G06N 3/08" ]	155,621
4,274,962	1987-10-07	36,926,794	Y	The present invention relates to novel compounds of the formula: (see above formula) useful in the treatment of epilepsy and other CNS disorders.	en	AMINO ACID DERIVATIVE ANTICONVULSANT	6318256_US	13350102_US,13350101_US	A61K 31/165,A61K 31/195,A61K 31/34,A61K 31/38,A61K 31/40,A61K 38/04,A61P 25/08,C07C 237/22,C07C 323/59,C07D 207/34,C07D 307/68,C07D 333/24	[ "C07C 237/22", "C07C 237/06", "C07D 333/24", "C07D 307/68", "C07D 307/66", "C07C 323/59", "C07D 207/34", "A61K 31/16", "C07D 207/327", "C07C 237/04", "A61K 31/341", "A61K 31/33", "A61K 31/34", "A61K 31/40", "A61K 31/165", "A61K 31/195", "A61K 31/38", "C07C 233/00", "A61K 31/381", "C07C 237/08", "A61K 38/00", "C07C 273/10", "A61K 38/04", "A61P 25/08" ]	3,738
48,425,351	1988-04-07	27,449,909	Y	Selective dopamine D1 receptor agonists for use in the treatment of primary degenerative dementia, depression, anxiety, obesity or schizophrenia.	en	Uses of dopamine receptor agonists	5243521_CH	6672201_CH,5444225_DE	A61K 31/00,A61K 31/40,A61K 31/475,A61K 31/48,A61P 3/04,A61P 25/18,A61P 25/24,A61P 25/26,A61P 25/28,A61P 43/00	[ "C07D 457/14", "A61K 31/475", "A61K 31/00", "A61P 25/26", "A61P 25/18", "A61P 25/24", "A61P 3/04", "A61K 45/00", "A61K 31/48", "A61P 25/28", "A61P 43/00" ]	37,180
48,793,823	1988-07-25	26,918,357	Y	Method of blocking 5HT without effect on alpha receptors with 1-loweralkyl-6-straight chain alkyl-8 beta -hydroxycycloalkyloxycarbonylergolines.	en	4-hydroxycyclohexyl 1-isopropyl-9,10-dihydro-lysergate for the treatment of migraine	5255150_US	5672952_US,6168678_US,5755752_US,5672949_US	A61K 31/48	[ "A61K 31/48" ]	37,772
549,449,450	2021-04-07	75,640,024	N	A method for treatment of viral infections, especially SARS-CoV-2 infections, said method comprising the administration of hydrolysable tannins.	en	HYDROLYSABLE TANNINS FOR USE IN MITIGATING ACUTE RESPIRATORY DISTRESS SYNDROME	57332079_US	13127287_US,43137885_US	A61K 9/2054,A61K 9/4866,A61K 31/366,A61K 31/4706,A61K 31/513,A61K 31/573,A61K 31/7004,A61K 31/7024,A61K 31/7048,A61K 31/706,A61K 36/185,A61K 36/36,A61K 36/47,A61K 36/53,A61K 36/81,A61K 36/87,A61P 11/00,A61P 31/14,A61P 37/04	[ "A61K 31/7048", "A61P 31/14", "A61K 31/366", "A61K 31/7024", "A61K 31/573", "A61K 31/4706", "A61K 31/513", "A61P 11/00", "A61K 31/706" ]	152,393
45,631,475	2001-09-24	22,886,745	Y	Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomicapplications.	en	HUMAN ION-EXCHANGER PROTEINS AND POLYNUCLEOTIDES ENCODING T HE SAME	13015564_US	37035729_,37028716_	A61K 38/00,C07K 14/705	[ "C12N 15/09", "C12N 1/21", "C12N 1/15", "C07K 14/705", "C12N 15/12", "A61K 38/00" ]	30,355
504,068,265	2016-05-17	56,008,637	N	The present principles proposes an invertible and low complexity inverse gamut mapper that preserves invariance of colors near the white point.	en	METHOD AND DEVICE FOR PROCESSING COLOR IMAGE DATA REPRESENTING COLORS OF A COLOR GAMUT	5371127_FR	6028554_FR,52532317_FR,54754172_FR	G09G 3/2003,G09G 5/02,G09G 5/10,G09G2340/06,H04N 1/6019,H04N 1/6058,H04N 19/186,H04N 19/85	[ "H04N 19/85", "H04N 19/186" ]	123,176
15,731,326	1993-05-07	25,468,285	Y	The invention relates to 5-(2-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-di hydro-2H-indol-2-one hydrochloride monohydrate.	en	Benzisothiazol-piperazinyl derivative and its use as neuroleptic	47609_US	828431_US	A61P 25/02,A61P 25/18,A61P 25/20,C07D 209/04,C07D 413/12,C07D 417/06,C07D 417/12	[ "A61K 31/47", "C07D 295/02", "C07D 263/54", "C07D 277/62", "A61K 31/427", "A61P 25/02", "C07D 417/14", "A61K 31/496", "C07D 215/38", "C07D 235/04", "C07D 209/04", "C07D 215/16", "A61P 25/20", "A61P 25/18", "C07D 417/12", "C07D 403/12", "A61K 31/495", "C07D 403/06", "C07D 249/18", "C07D 413/12" ]	12,523

4,849,713

2002-10-15

19,190,745

N

Use of cultured nerve stem cells originating in embryo stem cells in producing a remedy for dysmnesia. Thus, dysmnesia caused by Alzheimer~s disease, etc. can be treated.

en

REMEDY FOR DYSMNESIA

5220222_JP

16705059_JP,16802151_JP,16802153_JP,16802152_JP

A61K 35/12,A61P 25/00,A61P 25/28,C12N 5/0623,C12N2501/115,C12N2501/41,C12N2506/02

[ "C12N 5/0797", "C12N 5/0735", "A61K 35/30", "A61K 35/12", "C12N 5/07", "A61P 25/28", "A61K 35/48" ]

8,478

53,498,267

1985-11-04

9,291,831

Y

3,20-dione-11 beta -hydroxypregn-4-ene-21-thioacetate-17-butyrate and 3,20-dione-11 beta -hydroxypregn-4-ene-21-thiopropionate-17-butyrate, are anti-inflammatory agents.

en

Hydrocortisone 17-oxo-21-thioesters and their uses as medicaments

9988226_FR

5907728_FR,5907725_FR,5907726_FR,5907724_FR,5907727_FR

A61P 29/00,C07J 31/006

[ "C07J 31/00", "A61K 31/57", "A61P 29/00", "C07J 5/00" ]

46,233

16,519,325

1983-07-05

23,563,694

N

14-Fluoromorphinans such as 17-cyclopropylmethyl-4,5-epoxy-14-fluoro-3-hydroxymorphinan-6-one are useful as analgesics, narcotic antagonists, and/or anorexigenic agents.

en

Analgesic, antagonist, and/or anorectic 14-fluoromorphinans.

11691_US

2372110_US

A61P 3/04,A61P 25/04,A61P 25/30,C07D 489/06,C07D 489/08

[ "A61P 25/30", "A61K 31/485", "C07D 491/20", "C07D 489/08", "C07D 489/06", "A61P 25/04", "A61P 3/04" ]

17,314

408,622,029

2013-02-14

40,156,919

Y

The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycatioπ endproducts receptor (RAGE).

en

Methods of treatment using rage fusion proteins

12455287_US

5606230_US,9649388_US

A61K 38/00,A61K 39/39533,A61P 3/00,A61P 3/10,A61P 11/00,A61P 13/12,A61P 17/00,A61P 19/02,A61P 25/00,A61P 25/28,A61P 27/02,A61P 29/00,A61P 37/00,A61P 37/06,A61P 43/00,C07K 14/70503,C07K 19/00,C07K2319/30

[ "C07K 14/705", "A61K 39/395", "A61K 38/00" ]

80,909

51,074,423

1995-06-05

10,761,188

Y

This invention provides novel, optionally substituted tetrahydropyridoindoles which are useful serotonergic agents for the treatment of central nervous system disorders.

en

Serotonerbic tetrahydropyridoindoles

5255150_US

8264853_GB,5385049_GB,5385050_GB,6157413_GB,5385051_GB

C07D 471/04

[ "C07D 471/04" ]

41,207

502,832,134

2018-05-10

64,097,855

N

The components and structure for a genome created for the purpose of the evolutionary development of artificial intelligence systems/machines without human intervention.

en

Genome and self-evolution of AI

55946744_GB

C12Q 1/6869,G06N 3/008,G06N 3/086,G06N 3/123,G06N 3/126,G06N 20/00,G16B 5/00,G16B 20/00,G16B 20/20,G16B 20/50,G16B 25/00,G16B 30/00,G16B 40/00,G16B 50/00

[ "G06N 3/12", "G06F 19/22", "G06F 19/24", "G06N 3/08", "G06F 19/20", "G06F 19/28", "G06F 19/12", "G06F 19/18" ]

122,504

379,372,671

2012-06-22

47,362,494

N

A method and apparatus including a mobile device for administering and quantitatively determining a Risk Index that a user has suffered an impairment of brain function.

en

METHOD AND APPARATUS FOR MULTIMODAL MOBILE SCREENING TO QUANTITATIVELY DETECT BRAIN FUNCTION IMPAIRMENT

12289371_US,11078540_US,12289370_US,12289369_US

12289370_US,12289371_US,12289369_US

A61B 5/1124,A61B 5/162,A61B 5/163,A61B 5/378,A61B 5/4023,A61B 5/6898,A61B 5/7275,G16H 10/20,G16H 50/30

[ "A61B 5/11", "A61B 5/0484", "A61B 3/113" ]

77,607

340,704,440

2010-05-20

42,562,780

Y

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[

en

Modulators of 5-HT receptors and methods of use thereof

42601377_US,44136250_DE

16145925_,43361876_,43379696_,15019348_,15019350_,16162056_,37001291_,43379698_,37070407_,43379700_,43379695_,43379697_,43379694_,43379699_,40629277_

A61P 1/04,A61P 1/14,A61P 3/04,A61P 3/10,A61P 9/00,A61P 13/10,A61P 15/10,A61P 17/06,A61P 25/00,A61P 25/04,A61P 25/06,A61P 25/08,A61P 25/16,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/30,A61P 25/34,A61P 25/36,A61P 27/02,A61P 43/00,C07D 471/14,C07D 487/04,C07D 491/04,C07D 491/044,C07D 491/056,C07D 491/147,C07D 495/04,C07D 495/14,C07D 495/16,C07D 513/04

[ "A61K 31/551", "A61K 31/554", "A61P 25/00", "A61K 31/553", "C07D 495/04", "C07D 487/04", "C07D 491/04" ]

71,708

379,362,779

2010-11-19

44,991,967

Y

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[

en

Modulators of 5-HT receptors and methods of use thereof

44136250_DE,42601377_US

40629277_,43379695_,43379700_,43379697_,43379694_,16145925_,43379696_,43361876_,37070407_,15019348_,15019350_,43379698_,37001291_,16162056_,43379699_

A61K 31/55,A61P 1/00,A61P 1/04,A61P 1/14,A61P 3/00,A61P 3/04,A61P 3/10,A61P 9/12,A61P 13/10,A61P 15/00,A61P 15/10,A61P 17/06,A61P 19/08,A61P 25/00,A61P 25/04,A61P 25/06,A61P 25/08,A61P 25/14,A61P 25/16,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/30,A61P 25/34,A61P 27/02,A61P 27/06,A61P 29/00,A61P 43/00,C07B2200/13,C07D 209/94,C07D 471/14,C07D 487/04,C07D 491/04,C07D 491/044,C07D 491/147,C07D 495/04,C07D 495/14,C07D 513/04

[ "A61K 31/55", "A01N 43/46", "A01N 43/00" ]

77,572

405,387,702

2012-10-05

48,042,509

N

The present invention provides methods and systems for assessing cognitive function by comparing a subject's eye movements within and across distinct classes of images.

en

METHODS AND SYSTEMS FOR ASSESSING COGNITIVE FUNCTION

12373545_CA,10257084_CA

12373545_CA

A61B 3/032,A61B 3/113,A61B 5/163,A61B 5/165,A61B 5/4884,G16H 40/63,G16H 50/30

[ "A61B 3/032", "A61B 6/00" ]

79,235

55,856,128

2001-04-20

24,224,775

Y

13. A computer-readable medium comprising instructions that upon execution in a processor cause the processor to perform the methods as recited in any of claims 5 to 8.

en

Predictive dequantization of voiced speech

21051_US

30136_US,939523_US,49516734_IN,714758_US,49680237_US

G10L 19/0204,G10L 19/032,G10L 19/04,G10L 19/08,G10L 19/097,G10L 19/26,G10L 25/12

[ "G10L 25/90", "G10L 19/14", "H03M 7/36", "G10L 11/00", "G10L 19/08", "G10L 19/04", "G10L 19/02" ]

54,093

413,028,541

2013-05-29

49,671,097

N

A method of treating a patient with an ailment, comprises delivering ultrasound energy to a dorsal root ganglia (DRG), thereby modulating the DRG to treat the ailment.

en

ULTRASONIC MEANS AND METHODS FOR DORSAL ROOT GANGLION NEUROMODULATION

5344841_US

11403098_US,5230409_US

A61N 7/00,A61N 7/022,A61N2007/003,A61N2007/0078

[ "A61N 7/00" ]

83,600

267,301,114

2009-03-11

41,065,523

N

Provided are methods for treatment and prophylaxis of convulsive disorders and seizures, such as epilepsy and febrile seizures, by modulating TRPVl channel activation.

en

TREATMENT AND PROPHYLAXIS OF EPILEPSY AND FEBRILE SEIZURES

12540094_US,41002278_US,41002275_US,41002276_US,41002277_US

41002275_US,41002276_US,41002278_US,41002277_US

A61K 31/44,A61K 31/55,A61P 25/00,A61P 25/08

[ "A61K 31/55", "A61K 31/44", "A01N 43/56" ]

57,857

53,816,318

2001-05-10

27,807,159

N

Novel mammalian Zneu1 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.

en

Mammalian neuro-growth factor like protein

8217604_US

29519879_US,18458773_US

A61K 48/00,C07K 14/475,C07K2319/00

[ "C07K 14/475", "A61K 48/00" ]

47,204

329,267,118

2009-09-08

40,863,048

N

Subject matter disclosed herein may relate to a biometric security technique, and may relate to biometric identity verification and emotional stress state evaluation.

en

BIOMETRIC IDENTIFY VERIFICATION INCLUDING STRESS STATE EVALUATION

11590846_GB,11590847_GB,11590845_GB,5895541_GB

11590846_GB,11590847_GB,11590845_GB

C04B 41/009,C04B 41/4922,C04B 41/84,C04B2111/00965

[ "G05B 19/00" ]

65,163

335,684,469

2011-07-07

44,584,801

N

Certain embodiments of the present disclosure support techniques for power efficient implementation of neuron synapses with positive and/or negative synaptic weights.

en

METHODS AND SYSTEMS FOR CMOS IMPLEMENTATION OF NEURON SYNAPSE

12605958_US,12988305_US,5818520_US

12605958_US,12988305_US

G06N 3/049,G06N 3/0635,G11C 11/54

[ "G06N 3/063" ]

68,599

57,646,035

2008-10-14

40,753,767

Y

The present invention relates, in general, to perioperative depression and, in particular, to methods of identifying individuals at risk of perioperative depression.

en

Predictors of long-term mortality following coronary artery bypass graft surgery

10706874_US,10706871_US,10706870_US,10706876_US,5219375_US,11032243_US,11032244_US

10706870_US,11032244_US,10706876_US,10706874_US,10706871_US,11032243_US

C12Q 1/6883,C12Q2600/106,C12Q2600/156

[ "C12P 19/34", "C12Q 1/68" ]

56,490

524,926,015

2019-07-11

69,142,677

N

The present invention provides a method for promoting the functional maturation of a neural network by culturing neurons on a fiber sheet serving as a cell scaffold.

en

METHOD FOR FUNCTIONAL MATURATION OF NEURONS

74012124_JP,68510194_JP

73966571_JP,71195635_JP,71178089_JP,74392205_JP

C12Q 1/02

[ "C12N 5/0793", "C12N 5/0797", "C12Q 1/02" ]

136,065

51,813,794

2006-11-09

38,004,224

Y

The invention generally provides a biomarker for sleepiness, a method for detecting sleepiness, and a method of identifying nucleic acids associated with sleepiness.

en

Methods for detecting sleepiness

8829302_US,8829300_US,8829303_US,8829301_US,5348505_US

8829300_US,8829303_US,8829301_US,8829302_US

C12Q 1/40,C12Q 1/6883,C12Q2600/158,G01N2800/2864

[ "C12Q 1/40" ]

42,846

54,022,907

1992-06-04

15,697,565

Y

Antiferroelectric liquid crystal composition comprising at least one of antiferroelectric liquid crystal substances, and at least one of optically active substances.

en

Liquid crystal composition

5437228_JP

5302889_JP,5625441_JP,5493379_JP

C09K 19/0266,C09K 19/2021,C09K 19/586

[ "C09K 19/20", "C09K 19/54", "G02F 1/13", "C09K 19/02", "C09K 19/58" ]

47,872

267,456,895

2009-03-24

41,114,625

N

Materials and methods for identifying human natural anti-Aß autoantibodies, as well as materials and methods for using such antibodies to treat Alzheimer's disease.

en

HUMAN MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN, AND THEIR USE AS THERAPEUTIC AGENTS

36976054_US,5547498_US,41039785_US,13475849_US,41039784_US

41039785_US,41039784_US,13475849_US,36976054_US

A61P 25/28,C07K 16/18,C07K2317/21

[ "A61K 39/395", "A61P 25/28" ]

58,043

561,409,392

2021-05-19

78,608,184

N

Various embodiments of a system and associated method for determining a social structure in unstructured and/or structured social media forums are disclosed herein.

en

SYSTEMS AND METHODS FOR SOCIAL STRUCTURE CONSTRUCTION OF FORUMS USING INTERACTION COHERENCE

74795249_US,72422302_US,81899581_US,48323488_US

72422302_US,81899581_US

G06F 16/31,G06F 16/358,G06F 16/36,G06N 3/0454,G06N 3/08,G06N 20/00

[ "G06F 16/31", "G06N 20/00" ]

160,296

53,168,972

2003-12-23

34,108,383

N

A contrast card comprising at least two colored zones corresponding respectively to the average color of at least two regions of the face of a panel of individuals.

en

Cosmetic compositions and contrast cards for characterizing them

5317775_FR

39469056_FR,39469057_FR,22167461_FR

A45D 44/005,A45D2044/007,A61K 8/02,A61K 8/11,A61K 8/894,A61K2800/412,A61Q 1/02

[ "A61K 8/02", "A45D 44/00", "A61Q 1/02", "A61K 8/11", "A61K 8/894" ]

45,474

26,511,114

1976-03-16

26,249,900

Y

PURPOSE:A drug for improving and treating clouding of consciousness caused by head injury, cerebral operation, blood vessel lesion in brain, or cerebral tumor etc.

en

A DRUG FOR IMPROVING AND TREATING CLOUDING OF CONSCIOUSNESS

13636911_

30775800_,19703529_

A61K 38/066,A61P 25/28

[ "A61K 38/04", "A61K 38/06", "A61P 25/28" ]

24,413

4,757,935

2000-10-26

22,580,950

N

Polynucleotides, polypeptides, kits and methods are provided related to gene s expressed in the central nervous system that are regulated by neuroleptics.< /SDOAB>

en

REGULATION OF GENE EXPRESSION BY NEUROLEPTIC AGENTS

16674967_US

16582525_US,16700156_US,13455256_US,16713114_US,16713115_US

A61P 25/18,C07K 14/47

[ "C12N 1/15", "A61K 38/00", "C12Q 1/68", "C12N 15/09", "C12N 1/19", "C12N 5/10", "C12N 1/21", "C12P 21/08", "C07K 16/18", "A61K 39/395", "C07K 14/47", "A61P 25/18" ]

7,288

274,456,153

2008-01-31

41,608,921

N

Methods and apparatus for deriving a response time to a challenge in a network, and to a knowledge based quiz game suitable for use with the methods and apparatus.

en

Response time derivation and game

8867732_GB,11273709_GB,11273708_GB

8867732_GB,11273709_GB

G07F 17/32,G07F 17/3288,G07F 17/3295,H04L 63/0428,H04L2463/041

[ "A63F 13/00", "A63F 9/24" ]

60,217

554,801,430

2020-03-31

70,457,118

N

The present disclosure generally relates to activity trends and exercise, and more specifically to techniques for presenting activity trends and managing workouts.

en

Activity trends and workouts

58240756_

59040164_,59352766_,80256136_,64938449_,71350441_,58709090_,79875817_,75474505_,79841435_

A61B 5/112,A61B 5/1124,G06F 3/0483,G06F 3/04883,G06F 9/451,G16H 20/30,G16Y 10/65,G16Y 20/40,G16Y 40/10

[ "G06F 3/0483", "G06F 3/0488", "G06F 9/451", "G16Y 10/65", "G16Y 40/10", "G16Y 20/40" ]

155,981

559,321,269

2021-04-07

78,023,688

Y

A method of determining structured behavior from network adjacency matrices is described. A method of detecting physiological signals from a subject is described.

en

Method for uncovering deeply hidden enzyme-like behaviors from physiological time-series measures for disease detection, monitoring and other applications

81840442_US,56948003_US

56907649_US,56893160_US,6040234_US

A61B 5/0095,A61B 5/14542,A61B 5/14551,A61B 5/4064,A61B 5/4312,A61B 5/441,A61B 5/7246

[ "A61B 5/145" ]

159,038

53,909,756

2007-10-10

39,676,716

Y

This invention provides compounds of formula A and formula B which are modulators of potassium ion channels and are useful for the treatment of seizure disorders.

en

N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators

45164958_US,7385380_US,6341105_US,10300027_US,7629018_US

10300027_US,6341105_US,7629018_US,7385380_US

C07C 233/43,C07C 233/44,C07C 235/16,C07C 235/24,C07C 271/28

[ "A61K 31/167", "A61K 31/27", "C07C 271/28", "C07C 239/00", "C07C 237/00", "C07C 235/00", "C07C 233/00", "C07C 233/25" ]

47,509

48,885,447

1981-02-17

26,758,323

Y

The synthesis, resolution, radiolabeling and determination of the superior immunoreactivity of the syn isomer of a derivative of cortisol-21-acetate is described.

en

Preferential immunoreactivity of syn-isomer of cortisol derivative

5258882_US

7039233_US,5714211_US

C07J 41/0016

[ "C07J 41/00" ]

37,907

4,177,509

1983-02-10

23,392,697

Y

Title Antiinflammatory and/or Analgesic 2,3-Diaryl-5-Halo Thiophenes Certain 2,3-diaryl-5-halo thiophenes are useful in the treatment of inflammation and/or pain.

en

ANTIINFLAMMATORY AND/OR ANALGESIC 2,3-DIARYL-5-HALO THIOPHENES

15817366_

16091470_

A61P 25/04,A61P 29/00,C07D 333/28,C07D 409/04

[ "C07D 409/04", "A61K 31/44", "A61K 31/381", "C07D 333/28", "A61K 31/38", "A61P 29/00", "A61P 25/04", "A61K 31/4433" ]

3,487

48,727,963

1980-12-12

26,754,909

Y

Neuroleptically active octahydro-1H-pyrrolo[2,3-g]isoquinolines of the formula <IMAGE> A wherein R1, R2, R3, R4 and X are as hereinafter set forth, are described.

en

Octahydro-2-methyl-isoquinoline-6,8-dione

5244394_US

5278373_US,5259436_US

C07D 209/08,C07D 217/04,C07D 471/04

[ "C07D 209/08", "C07D 471/04", "C07D 217/04" ]

37,673

29,496

2008-01-04

39,594,365

N

We present a novel design for an optical differential quadrature phase shift keying modulator comprised of two intensity modulators in a three-arm interferometer.

en

COMPACT OPTICAL MODULATOR

12490364_US,5273833_US

12490364_US

H04B 10/505,H04B 10/5561

[ "H04B 10/155" ]

109

4,758,016

2000-10-26

22,586,846

N

Novel 5-benzyl-octahydroindoles and 6-benzyl-decahydroquinolines substituted in the 1-position are effective as NMDA NR2B antagonists useful for relievin g pain.

en

5-BENZYL-OCTAHYDROINDOLE AND 6-BENZYL-DECAHYDROQUINOLINE NMDA/NR2B ANTAGONISTS

7460330_US

16596289_US,12705490_US,12488961_US

A61P 9/00,A61P 25/00,A61P 25/04,A61P 25/06,A61P 25/16,A61P 25/18,A61P 25/22,A61P 25/24,C07D 209/10,C07D 215/06,C07D 235/06

[ "A61P 25/04", "A61P 25/06", "A61P 25/00", "A61P 9/00", "A61P 25/22", "A61P 25/24", "C07D 209/10", "C07D 403/06", "C07D 209/08", "C07D 215/06", "C07D 235/06", "C07D 401/06", "A61P 25/18", "A61K 31/404", "A61P 25/16", "A61K 31/4184", "A61K 31/4709", "A61K 31/4178" ]

7,289

546,530,188

2020-08-25

74,684,531

N

The present invention provides genetic markers associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.

en

GENETIC VARIANTS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE

12489970_CN

44354467_CN,80733166_CN,41265035_CN,13167591_CN,57473192_CN,57436762_CN

A61K 31/496,A61K 45/06,A61P 25/28,C12Q 1/6883,C12Q2600/156,G01N 33/6896

[ "A61P 25/28", "A61K 31/496", "C12Q 1/68" ]

150,617

526,995,624

2018-05-02

58,709,424

N

The invention also provides the use of means for determining the amount of miR218-5p for predicting subject's responsiveness to a corticosteroid medical regimen.

en

PREDICTIVE RESPONSE BIOMARKERS TO CORTICOSTEROIDS

55847469_ES,48319979_ES

74641049_ES,74708921_ES,74720830_ES,74787723_ES

C12Q 1/6883,C12Q2600/178

[ "C12Q 1/6883" ]

137,313

381,253,848

2012-10-23

39,152,127

N

A cell line and an assay for discovering neurogenic drugs are described. The assay allows for systematic screening of test agents such as libraries of compounds.

en

METHOD FOR DISCOVERING NEUROGENIC AGENTS

7327797_US,7327797_US

5867952_US,5704995_US

G01N 33/5058

[ "C12N 5/0797", "G01N 33/53" ]

78,426

17,036,094

1994-04-09

22,014,118

Y

An asymmetrical hydroxyphenyl benzotriazolylphenol cpd. of formula (I) is new. In (I), R1 = methyl; R2 = octyl; and X = H, halogen, 1-12C alkyl, or 1-12C alkoxy.

en

Asymmetrical benzotriazolylphenols

554714_US

3319391_US,3319390_US

C07D 249/20

[ "C07D 249/20" ]

18,500

471,114,781

2016-07-14

49,989,665

Y

as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 4 (mGluR4) and/or altering glutamate level or glutamatergic signalling.

en

Substituted quinoxalines as positive allosteric modulators of mGluR4

5223450_DE

8382210_US

A61K 31/498,A61P 1/00,A61P 3/10,A61P 25/00,A61P 27/00,A61P 35/00,A61P 43/00,C07D 241/38,C07D 241/42,C07D 401/04,C07D 403/04

[ "C07D 241/36", "C07D 241/42", "C07D 241/38", "C07D 401/04", "A61K 31/498" ]

104,634

443,850,016

2015-02-20

53,882,484

N

The present disclosure relates to a system and method for generating survey questions, and to a system and method for managing behavioral health using the same.

en

SYSTEM AND METHOD FOR GENERATING SURVEY QUESTIONS

51515060_US

51532375_US,51492440_US,51569237_US,51463889_US,51418214_US

G16H 10/20,G16Z 99/00

[ "G06F 19/00" ]

95,392

440,698,470

2010-12-08

43,629,588

N

Disclosed is an antibody which binds to C4.4a comprising CDR sequences of FSNAWMSWV, VSYISSSGSTIYYADSVKGR, AREGLWAFDY, TGSSSNIGAGYVVH, DNNKRPS and CAAWDDRLNGPV.

en

Anti-c4.4a antibodies and uses thereof

15021570_

50298851_,39059210_,19716550_,44065192_,39457575_,44065191_,43906587_,44177493_,44177492_,44177494_,44177490_,44177491_

A61K 38/17,A61K 39/395,A61K 39/39558,A61K 47/42,A61K 48/00,A61K 49/16,A61K2039/505,A61P 35/00,A61P 35/04,C07K 14/435,C07K 14/475,C07K 16/18,C07K 16/22,C07K 16/28,C07K 16/30,C07K2317/21,C07K2317/33,C07K2317/55,C07K2317/56,C07K2317/565,C07K2317/73,C07K2317/732,C07K2317/77,C07K2317/92

[ "A61K 39/395", "C07K 16/30", "A61P 35/00", "G01N 33/53" ]

93,708

408,624,382

2013-03-01

48,744,381

N

A system for identifying the connectivity between different brain regions to determine the functional role of brain regions in various human and animal actions.

en

FUNCTIONAL EEG IMAGER

12456410_US,12138161_US,12138162_US

12456410_US,12138162_US

A61B 5/296,A61B 5/316,A61B 5/377,A61B 5/389,A61B 5/4064,A61B 5/4082,A61B 5/4244,A61B 5/6806,A61B 5/7203,A61B 5/742

[ "A61B 5/00", "A61B 5/0484", "A61B 5/04" ]

80,929

42,205,755

2001-03-30

20,279,146

N

A compound of formula I for use in therapy such as pain management, gastrointestinal disorders, spinal injuries or disorders of the sympathetic nervous system.

en

Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain

5465253_

13022271_,13022270_,13048877_

A61K 31/445,A61P 1/00,A61P 25/00,A61P 25/02,A61P 25/04,C07D 211/70,C07D 401/06,C07D 405/06,C07D 409/06,C07D 417/06

[ "A61P 25/00", "C07D 409/06", "A61K 31/4535", "A61K 31/4525", "A61P 1/00", "A61K 31/4545", "A61P 25/02", "C07D 405/06", "C07D 401/06", "A61P 25/04", "C07D 211/70", "C07D 211/68", "C07D 417/06", "A61K 31/4523", "A61K 31/4465" ]

28,178

11,080,239

1988-09-17

6,336,979

N

2-Carbamoyloxyphenyl phosphoro(di)thioate esters of formula (I) are new: R1 = 1-4C alkyl; R2 = H, 1-4C alkyl or 1-4C alkoxy; R3 = H or 1-4C alkyl; X = O or S.

en

O-(O-ETHYL-S-ALKYLPHOSPHORYL)-O-(CARBAMOYL)-BRENZKATECHINDERIVATE.

21465212_DE

22969277_DE,22969279_DE,22764122_DE,22848990_DE,22969278_DE

A01N 57/14,C07F 9/18

[ "A01N 57/14", "C07F 9/18" ]

11,103

525,255,352

2018-02-22

59,521,217

N

The invention further discloses a corresponding method for producing a cranial operculum for a living being, in particular implemented by means of a computer.

en

SYSTEM AND METHOD FOR PRODUCING A CRANIAL OPERCULUM FOR A LIVING BEING

72400901_IT

72306057_IT,72338306_IT,72296259_IT,72317735_IT

A61B 34/10,A61B2034/104,A61B2034/105,A61F 2/2875,A61F 2/30942,A61F2002/30578,A61F2002/30948,A61F2002/30952,A61F2002/30962,A61F2002/30985,B33Y 50/00,G05B 19/4097

[ "A61B 34/10", "B33Y 50/00", "A61F 2/28", "G05B 19/4097", "A61F 2/30" ]

136,373

48,848,306

1981-02-02

26,910,682

Y

Neuroleptically active cycloalka[4,5]pyrrolo[2,3-g]isoquinolines of the formula <IMAGE> A wherein n, R1, R2 and X are as hereinafter set forth, are described.

en

Cycloalka[4,5]pyrrolo[2,3-g]isoquinolines

5244394_US

5259436_US,5278373_US

C07D 209/88,C07D 217/04,C07D 471/04

[ "C07D 471/04", "C07D 217/04", "C07D 209/88" ]

37,841

509,128,988

2018-09-13

65,630,090

N

Provided herein are devices, systems, and methods, for capturing perioperative intracranial ultrasound images and for determining elasticity of brain tissue.

en

Ultrasound-Enabled Fiducials for Real-Time Detection of Brain Shift During Neurosurgery

52615275_US

69931167_CA

A61B 5/0042,A61B 5/031,A61B 5/4064,A61B 5/7267,A61B 8/0808,A61B 8/085,A61B 8/12,A61B 8/14,A61B 8/4444,A61B 8/463,A61B 8/481,A61B 8/485,A61B 8/488,A61B 8/5223,A61B 8/5246,A61B 8/5261,A61B 90/11,A61B 90/36,A61B 90/37,A61B 90/39,A61B2090/103,A61B2090/363,A61B2090/364,A61B2090/378,A61B2090/3925,A61B2090/3954,A61B2090/3966,A61B2090/3991,A61B2090/3995

[ "A61B 8/08", "A61B 90/00" ]

125,875

47,405,412

1998-10-23

22,046,368

N

Methods for specifically inactivating myelin proteins which inhibit nerve regeneration are described. These methods are useful to promote axon regeneration.

en

LASER INACTIVATION OF INHIBITORY MOLECULES IN CENTRAL NERVOUS SY STEM MYELIN

6104054_US,25604445_US

25604445_US

A61N 5/0601,A61N 5/062

[ "A61K 41/00", "A61N 5/06" ]

35,526

494,666,007

2017-11-20

62,145,857

N

The present invention relates to novel small molecule modulators of Nav1.6 channels of the general formulae (I), (II), (III) and (IV), and the uses thereof.

en

FINE-TUNE MODULATORS OF NEURONAL EXCITABILITY FOR NEUROPSYCHIATRIC DISORDERS

6893329_US

57696139_US,12327988_US,12618028_US,57396408_US

A61K 31/401,A61K 31/427,A61K 31/5377,A61K 38/1825,A61K 45/06,C07C 237/52,C07D 207/16,C07D 413/12,C07D 417/12,C07K 5/0808,C07K 5/0812,C07K 5/1016

[ "A61K 31/11", "C07D 207/00", "C07C 47/06", "C07C 47/02", "A61K 31/40", "A61K 31/401" ]

117,846

438,137,873

2014-09-09

37,806,954

Y

The invention provides methods of treating Friedreich's ataxia and other neurodegenerative or neuromuscular conditions using histone deacetylase inhibitors.

en

Treatment of friedreich's ataxia using histone deacetylase inhibitors

5258289_US

6251543_US,49874261_DE,9062919_US,9062920_US,6251544_US

A61J 1/00,A61K 31/167,A61P 25/00,A61P 25/14,A61P 25/28,C07C 225/10,C07C 231/00,C07C 231/02,C07C 233/07,C07C 233/25,C07C 233/29,C07C 233/43,C07C 233/44,C07D 213/75,C07D 215/38,C07D 215/40

[ "C07D 215/40", "A61J 1/00", "C07C 233/43", "C07C 233/25" ]

92,362

54,559,056

2005-07-25

35,733,672

N

An auditory theme represents at least one participant in a networked (102) group (104, 105, 106) interaction, and reflects an attribute of that participant.

en

THEMES INDICATIVE OF PARTICIPANTS IN PERSISTENT COMMUNICATION

6802822_US,6802824_US,6802821_US,39753230_US,5904088_US,39742245_US

39753230_US,6802822_US,6802821_US,39742245_US,6802824_US

G06F 3/165,G06Q 50/30,H04L 12/18,H04L 12/1813,H04L 51/043,H04L 65/403,H04L 67/131

[ "G06F 15/16" ]

50,476

317,678,739

2005-08-15

41,559,733

Y

A question and answer game includes more than one answer choice to each question and each answer choice has a strategic element with a risk/reward tradeoff.

en

Multiplayer game with strategic element

11451408_US,11260129_US,11451407_US

11260129_US,11451408_US

A63F 9/18,A63F 9/183,G07F 17/3276,G07F 17/3295

[ "A63F 1/00" ]

62,832

421,096,929

2013-12-05

39,588,961

Y

Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression.

en

Use of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid in treating symptoms associated with rett syndrome

8698530_FR,5219886_CH,11350507_CH,8944822_CH,12208728_CH,11350508_CH,8897738_CH,8944831_CH

8944831_CH,11350508_CH,8698530_FR,11350507_CH,8897738_CH,8944822_CH,12208728_CH

A61K 31/137,A61K 31/138,A61K 31/145,A61K 31/397,A61K 45/06,A61P 3/04,A61P 3/10,A61P 17/02,A61P 25/00,A61P 25/14,A61P 25/16,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 37/00,A61P 43/00

[ "A61K 31/137", "A61K 45/06", "A61K 31/397", "A61K 31/145", "A61K 31/138" ]

88,109

45,016,167

1998-08-18

27,369,092

Y

GABA analogs are useful to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome. Preferred treatments employ gabapentin or pregabalin.

en

Pharmaceutical composition for preventing and treating gastrointestinal damage and disorders, ethanol withdrawal syndrome, or pain

13071897_US,5355881_US

36715628_GB,16620941_US,36715627_CN,12700887_IT,36715629_US

A61K 31/195,A61K 31/197,A61K 31/40,A61K 31/405,A61K 31/42,A61K 31/54,A61K 31/60,A61K 45/06,A61P 1/00,A61P 1/04,A61P 25/32,A61P 29/00

[ "A61K 31/42", "A61K 45/06", "A61P 25/32", "A61K 31/405", "A61K 31/197", "A61K 31/40", "A61K 31/60", "A61K 31/195", "A61K 31/54", "A61P 1/04", "A61P 1/00" ]

28,975

227,090

2005-07-12

35,106,735

N

The invention relates to a method for the treatment of anorexia nervosa comprising the administration of a therapeutically effective amount of flibanserin.

en

USE OF FLIBANSERIN FOR THE TREATMENT OF ANOREXIA NERVOSA

142392_US

358913_US

A61K 31/496,A61P 1/14,A61P 25/24,A61P 43/00

[ "A61P 25/24", "A61K 31/496" ]

1,241

417,619,168

2014-01-14

36,889,233

N

The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus.

en

METHODS OF TREATING REFRACTORY REPETITIVE SEIZURES

5242161_DE

10805651_DE

A61K 9/0053,A61K 31/165,A61K 31/4015,A61K 31/55,A61K 31/5513,A61K 38/04,A61K 45/06,A61K2300/00,A61P 25/00,A61P 25/08,A61P 25/12,G01N 33/6893

[ "A61K 45/06", "A61K 31/165", "A61K 31/5513" ]

86,259

15,658,533

1991-07-31

6,411,708

Y

2-Phenyl-1,2-benzisoselenazol-3(2H)-one(Ebselen) is capable of reducing the cisplatin-induced nephrotoxicity and neurotoxicity during cytostatic treatment.

en

USE OF 2-PHENYL-1,2-BENZISOSELENAZOL-3(2H)-ONE

25618505_DE

25618506_NL,25618508_NL,25618511_NL,25618507_NL,25618510_NL,25618509_GB

A61K 31/41,A61K 33/243,A61P 35/00,A61P 43/00

[ "A61P 35/00", "A61K 33/24", "A61K 31/41", "A61K 31/28", "A61P 43/00", "C07D 293/06", "C07D 293/12" ]

12,201

4,241,385

1986-02-21

25,829,707

Y

The present invention relates to the combination of flupirtin and antichoilinergically aciting spasmolytics, having a synergistic effect at the same time.

en

COMBINATION OF FLUPIRTIN AND ANTICHOLINERGICALLY ACTING SPASMOLYTICS

12650811_

16144536_DE,16144534_DE,13093275_DE,16144535_DE,10333786_DE

A61K 31/44,A61K 31/46

[ "A61K 31/46", "A61K 31/44" ]

3,643

50,237,423

1970-05-06

21,879,676

Y

The acoustic impedance of the cornea is measured by comparing the energy it reflects with the energy reflected by a calibrated, variable impedance member.

en

MEANS AND METHOD FOR DETECTION OF GLAUCOMA

38685658_,13813512_

13813512_,38685658_

A61B 3/165,A61B 8/10

[ "A61B 8/10", "A61B 3/16" ]

39,752

338,131,277

2009-11-04

42,153,522

N

The present invention relates to techniques and systems for training a subject to modify his or her own neutronal activity within a selected brain region.

en

Drug-Enhanced Neurofeedback

11907425_US,5536866_US,11103405_US

11103405_US,11907425_US

A61B 5/055,A61B 5/375,A61B 5/486,A61B 6/037,A61K 31/197,A61K 31/198,A61K 31/42,A61K 45/06,A61P 25/00,G01N 33/9406,G01N2333/70571,G01R 33/4806,G09B 5/02,G09B 5/04,G09B 23/28

[ "A61P 25/00", "A61K 49/00", "G09B 19/00" ]

70,233

53,535,321

2001-03-07

26,883,189

Y

Methods relating to the use of neonatal animals to identify sleep wake states in the corresponding adults and/or phenotypically characterize such adults.

en

Analysis of muscular activity in neonatal animals to screen for mutations and/or drugs that alter sleep and wake states

5266690_US

10016249_US,10016248_US

A01K 29/00,A01K 29/005

[ "A01K 29/00" ]

46,336

54,422,530

2004-11-03

34,657,052

N

The present invention relates to the use of inhibitors of PACAP receptor activity for the treatment of pelvic floor pain syndrome and overactive bladder.

en

Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome

12502946_US

39667964_US,39667963_US

A61K2039/505,C07K 16/26,C07K 16/2869

[ "C07K 16/28", "C07K 16/26" ]

49,190

53,665,294

1986-02-03

25,577,460

Y

A peptide having the amino acid sequence Asp-Ser-Glu-Pro-Arg and capable of blocking immune complex binding to immunoglobulin Fc receptors is disclosed.

en

Immunotherapeutic antiallergic polypeptide agents which bind to basophil immunoglobin Fc receptors

7864128_US

10114364_US

A61K 38/00,C07K 16/065

[ "C07K 16/06", "A61K 38/00" ]

46,728

16,238,530

2005-03-24

34,993,449

N

A therapeutic and/or preventive agent for inner ear disorders comprising an IL-6 antagonist, preferably an anti-IL-6R antibody, as an active ingredient.

en

THERAPEUTIC AGENT FOR AURIS INTERNA DISORDER CONTAINING IL-6 ANTAGONIST AS ACTIVE INGREDIENT

50652_JP,6211_JP

1841634_JP,1841636_JP,1841635_JP,1841633_JP,226553_JP

A61K2039/505,A61P 19/08,A61P 25/02,A61P 27/16,A61P 29/00,A61P 31/12,A61P 35/00,A61P 43/00,C07K 16/2866

[ "A61P 27/16", "A61P 19/08", "A61P 25/02", "A61K 45/00", "C07K 16/28", "A61P 43/00", "A61P 31/12", "A61P 29/00", "A61P 35/00", "A61K 39/395" ]

16,183

518,106,589

2019-02-13

67,616,358

N

Methods are disclosed for treating inflammation and sepsis and for promoting thermoregulation by activating neurons expressing TRPA1 in the vagus nerve.

en

ACTIVATION OF TRPA1+ NOCICEPTORS IN THE VAGUS NERVE ATTENUATES SYSTEMIC INFLAMMATION

5224749_US

5224750_US,55887194_US,72432352_US

A61K 31/4439,A61K 41/0057,A61P 29/00,A61P 31/04

[ "A61K 31/4439", "A61P 29/00", "A61P 31/04", "A61K 41/00" ]

130,813

52,347,926

1984-07-12

27,069,019

Y

1-(2-Aryl-2-halo-1-ethenyl)-1_H-azoles having anticonvulsant properties which are particularly useful in the treatment of generalized forms of epilepsy.

en

1-(2-Aryl-2-halo-1-ethenyl)-1_H-azoles, and anticonvulsant use thereof

5223476_BE

5249841_BE

A61P 25/08,C07D 231/12,C07D 233/56,C07D 249/08

[ "C07D 521/00", "C07D 233/61", "C07D 333/00", "C07D 409/06", "C07D 249/08", "A61K 31/4164", "C07D 233/60", "C07D 233/56", "A61K 31/41", "A61K 31/415", "A61P 25/08", "A61K 31/4196" ]

43,890

530,427,680

2014-12-12

52,293,220

Y

Compound of formula (I), (I) pharmaceutical compositions on the basis thereof, and their usage for various disorders treatment including pain. Table: 9

en

PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS

9690471_US

A61K 31/675,A61K 31/685,A61K 45/06,A61P 1/00,A61P 1/02,A61P 1/06,A61P 9/06,A61P 11/14,A61P 13/00,A61P 13/02,A61P 19/00,A61P 19/02,A61P 21/00,A61P 25/00,A61P 25/02,A61P 25/04,A61P 29/00,A61P 43/00,C07D 213/18,C07F 9/576,C07F 9/58,C07F 9/59

[ "A61P 19/02", "C07F 9/576", "A61K 31/675" ]

139,738

52,477,830

1984-09-05

27,082,909

Y

This application relates to 4-amino-4,5-dihydro-2-thiophenecarboxylic acid, the C1-6 alkyl esters thereof and to their use in the treatment of epilepsy.

en

alpha -Aminobutyric acid transaminase inhibitors

5266511_US

6547115_US,9326132_US,6547114_US

C07D 333/38

[ "C07D 333/38" ]

44,124

53,587,949

2004-03-26

33,131,717

N

Disclosed are methods of identifying psychoactive agents, e.g., anti-depressant, anti-psychotic or opioid compound, using differential gene expression.

en

Psychoactive compound associated markers and method of use thereof

36937222_,39552690_,28909722_

36937245_US,39552691_US,36937246_US

C12Q 1/6883,C12Q2600/158,G01N 33/5008,G01N 33/5023,G01N 33/5058,G01N 33/94,G01N 33/9486

[ "C12Q 1/68", "G01N 33/94", "G01N 33/50", "G01N" ]

46,511

535,813,029

2020-02-04

71,836,700

N

The present disclosure relates to a mixed-reality therapy system is configured to provide tasks and prompts to a user and monitor the user's responses.

en

Mixed-Reality Autism Spectrum Disorder Therapy

74825685_US

74822355_US,74784410_US,74751715_US,74715034_US

A61M 21/00,A61M2021/005,A61M2205/3306,A61M2205/3375,A61M2205/3553,A61M2205/3584,A61M2205/3592,A61M2205/502,A61M2209/088,A61M2230/63,G06F 3/011,G06F 3/013,G06F 3/0482,G06F 3/0484,G06F 3/04842,G06F 3/147,G06F2203/011,G06V 40/174,G06V 40/18,G09G 5/37,G09G2340/12,G09G2354/00,G09G2380/08,G16H 20/70,G16H 40/67

[ "G06F 3/0484", "G09G 5/37", "G06K 9/00", "G16H 20/70", "G06F 3/01", "G16H 40/67", "A61M 21/00" ]

143,165

48,939,718

1981-03-09

26,839,413

Y

Octahydro-2H-pyrrolo[3,4-g]quinolines, useful as dopamine agonists, particularly as inhibitors of prolactin secretion and in treatment of Parkinsonism.

en

Octahydro-2H-pyrrolo[3,4,-g]quinolines

5255150_US

5259702_US,5259701_US

C07D 215/20,C07D 215/227,C07D 471/04

[ "C07D 215/20", "C07D 215/227", "C07D 215/22", "C07D 471/04" ]

38,002

48,118,712

1980-04-18

26,707,467

Y

Octahydro-2H-pyrrolo[3,4-g]quinolines, useful as dopamine agonists, particularly as inhibitors of prolactin secretion and in treatment of Parkinsonism.

en

Octahydro-2H-pyrrolo[3,4-g]quinolines

5255150_US

5259702_US,5259701_US

C07D 215/20,C07D 215/227,C07D 471/04

[ "C07D 215/227", "C07D 215/22", "C07D 471/04", "C07D 215/20" ]

36,699

51,874,851

1975-04-08

27,003,116

Y

Certain 4a-aryl-trans-decahydroisoquinolines are useful as analgesics. Exemplary is N-cyclopropylmethyl-4a-m-hydroxyphenyl-trans-decahydroisoquinoline.

en

4a-Aryl-trans-decahydroisoquinolines

5404506_US

6332377_US,7160045_US

C07D 217/02,C07D 217/04,C07D 217/16,C07D 217/24,C07D 317/62

[ "C07D 217/02", "C07D 217/04", "C07D 217/16", "C07D 317/62", "C07D 217/24" ]

42,963

416,628,802

2013-09-17

46,851,875

Y

Denne opfindelse angår reagenser samt reagenser til anvendelse i behandling, diagnosticering og sporing af sygdomme i forbindelse med lakse-alphavirus.

en

Fiskevaccine

52231432_CH

51905862_GB,51814361_CA

A61K 39/12,A61K2039/53,A61K2039/552,A61K2039/55566,C07K 14/005,C12N 7/00,C12N2770/36122,C12N2770/36134

[ "C07K 14/18", "A61K 39/12" ]

85,580

339,405,687

2009-04-27

41,255,710

N

Disclosed are methods for diagnosing AMD or a susceptibility for AMD by identifying one or more markers associated with peripheral retinal phenotypes.

en

Polynucleotides Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risks

5219722_US,10979441_US,5867956_US,6327013_US

10979441_US,5867956_US

C12Q 1/6883,C12Q2600/172

[ "C40B 30/04" ]

70,916

500,783,133

2018-06-01

63,670,424

Y

The present invention provides a method for clinically identifying Parkinson disease with normal cognition or Parkinson disease dementia in a subject.

en

Method for discriminating Parkinson's disease dementia from Parkinson's disease with normal cognition

48378190_TW

50041614_TW

B82Y 5/00,B82Y 25/00,G01N 33/5005,G01N 33/54326,G01N 33/6896,G01N2800/2835,G16B 20/00,G16H 50/20,H01F 1/0054,H01F 1/344

[ "G01N 33/50", "H01F 1/34", "G01N 33/543", "G01N 33/68" ]

121,285

336,623,704

2011-02-25

44,505,484

N

The present invention provides diagnostic and disease progression or recurrence prediction methods based on osteopontin levels in a biological sample.

en

Asbestos Exposure, Pleural Mesothelioma and Osteopontin Levels

5726689_US,11854225_US,5283479_US,11854226_US

11854226_US,11854225_US

G01N 33/57423,G01N 33/57488,G01N2333/52,G01N2800/56

[ "G01N 33/566" ]

69,297

54,390,075

1978-12-22

6,027,555

Y

Estradiol valerate has been discovered to possess neuropsychotropic activity, e.g., it is an effective anti-depressant having advantageous properties.

en

Use of estradiol valerate as an anti-depressant

5244541_DE

6028648_US,9206509_DE,10685466_DE

A61K 31/565,C07J 1/0074

[ "C07J 1/00", "A61K 31/565" ]

49,034

339,622,484

2011-08-04

45,065,201

N

A system and method for assessing engagement activities and influence using consumer-specific promotions in a social network environment is provided.

en

Assessing engagement and influence using consumer-specific promotions in social networks

11768456_US,11768457_US,11227980_US,8272137_US

11227980_US,11768457_US,11768456_US,8272137_US

G06Q 30/02,G06Q 30/0211

[ "G06Q 30/00" ]

71,043

422,250,595

2014-03-14

51,581,757

N

Compositions and methods for the identification of agents useful for the treatment of neurological disorders, including schizophrenia, are provided.

en

SCHIZOPHRENIA-ASSOCIATED GENETIC LOCI IDENTIFIED IN GENOME WIDE ASSOCIATION STUDIES AND USE THEREOF AS NOVEL THERAPEUTIC TARGETS

12476372_US

12592816_US,49022414_US

A61P 25/00,C12Q 1/6883,C12Q2600/106,C12Q2600/156,G01N 33/5008,G01N 33/6803,G01N2500/04,G01N2500/10,G01N2800/30,G01N2800/302,G01N2800/304

[ "C40B 30/04", "G01N 33/53", "A61P 25/00" ]

89,070

52,641,461

1984-11-09

27,036,145

Y

Compounds of the class of loweralkyl N-[amino(arylaminocarbonyl)iminomethyl]-N-methylglycinate acid addition salts are useful as antianxiety agents.

en

Anxiety alleviating compositions containing loweralkyl-N-[amino(arylaminocarbonyl)-iminomethyl]-N-methylglycinates

5248635_US

5395478_US

A61K 31/24

[ "A61K 31/24" ]

44,432

51,635,923

2000-03-24

26,824,079

Y

A method of treating an obsessive-compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual.

en

Methods of treating obsessive-compulsive spectrum disorders

5297847_US

8676220_US,8676221_US,8676222_US

A61K 31/135,A61K 31/15,A61K 31/4525,A61K 31/55

[ "A61K 31/4525", "A61K 31/15", "A61K 31/55", "A61K 31/135" ]

42,496

378,959,309

2012-03-01

46,798,708

N

This invention provides gene expression profiles useful for diagnosing lacunar stroke and for distinguishing lacunar stroke from non-lacunar stroke.

en

BIOMARKERS FOR THE DIAGNOSIS OF LACUNAR STROKE

11471308_US,11981845_US,5211659_US

11981845_US,11471308_US

C12Q 1/6883,C12Q2600/112,C12Q2600/158,C40B 40/06,G01N 33/6893,G01N2800/2871

[ "C40B 40/06", "C40B 30/04" ]

77,366

42,197,359

1999-06-18

22,231,857

N

A GABA analog and decongestant combination is used to treat sinus headache and sinus pain. The GABA analog can be either gabapentin or pregabalin.

en

Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain

6603839_

33973472_,33973473_

A61K 31/195,A61P 25/04,A61P 29/00,A61P 29/02,A61P 43/00

[ "A61K 31/195", "A61P 43/00", "A61P 25/04", "A61K 31/197" ]

27,996

52,049,704

2005-02-17

34,910,765

N

The invention provides methods and compositions for treating anxiety and fear disorders through inhibition of alpha-2,8-sialyltransferase activity.

en

Anxiolytic treatment by inhibition of a polysialyltransferase

9028049_US,9028050_US

9028051_US,6040561_US

A61K 31/00,A61K 31/715,G01N 33/6896,G01N2333/91148,G01N2500/04,G01N2800/301

[ "A61K 31/715" ]

43,337

352,824,421

2001-04-26

27,072,208

Y

COMPOUNDS OF FORMULA I(I)@PHARMACEUTICAL COMPOSITIONS OF THESE COMPOUNDS, AND USE OF SAID COMPOSITIONS TO CONTROL SYNAPTIC TRANSMISSION IN MAMMALS.

en

DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS

5634013_US

42864605_US,34162388_US,34148106_US,34148107_US,34148108_US,34148103_US,34145556_US,33569142_US,34148102_US

A61P 1/00,A61P 13/00,A61P 15/10,A61P 25/00,A61P 25/04,A61P 25/06,A61P 25/08,A61P 25/14,A61P 25/16,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/34,C07D 471/04,C07D 487/04

[ "A61K 31/4545", "A61P 25/16", "A61P 25/24", "A61K 31/454", "C07D 231/54", "C07D 487/04", "C07D 471/04", "A61P 25/34", "A61P 25/00", "A61P 25/14", "A61P 25/04", "A61P 25/18", "A61P 25/28" ]

73,020

378,944,191

2012-11-09

47,428,966

N

Certain aspects of the present disclosure support techniques for unsupervised neural replay, learning refinement, association and memory transfer.

en

METHODS AND APPARATUS FOR UNSUPERVISED NEURAL REPLAY, LEARNING REFINEMENT, ASSOCIATION AND MEMORY TRANSFER: NEURAL ASSOCIATIVE LEARNING, PATTERN COMPLETION, SEPARATION, GENERALIZATION AND HIERARCHICAL REPLAY

5818520_US

41923840_US,43867151_US

G06N 3/04,G06N 3/049,G06N 3/08

[ "G06N 3/04" ]

77,343

378,715,914

2012-11-09

47,295,178

N

Certain aspects of the present disclosure support techniques for unsupervised neural replay, learning refinement, association and memory transfer.

en

METHODS AND APPARATUS FOR UNSUPERVISED NEURAL REPLAY, LEARNING REFINEMENT, ASSOCIATION AND MEMORY TRANSFER: NEURAL COMPONENT MEMORY TRANSFER

5818520_US

41923840_US,43867151_US

G06N 3/04,G06N 3/0409,G06N 3/049,G06N 3/08,G06N 3/082

[ "G06N 3/08", "G06N 3/04" ]

77,191

378,622,216

2012-11-09

47,428,967

N

Certain aspects of the present disclosure support techniques for unsupervised neural replay, learning refinement, association and memory transfer.

en

METHODS AND APPARATUS FOR UNSUPERVISED NEURAL REPLAY, LEARNING REFINEMENT, ASSOCIATION AND MEMORY TRANSFER: NEURAL COMPONENT REPLAY

5818520_US

43867151_US,41923840_US

G06N 3/04,G06N 3/049,G06N 3/08,G06N 3/082

[ "G06N 3/08", "G06N 3/04" ]

77,120

52,980,683

1991-06-17

27,060,106

Y

A dosage form is disclosed comprising an anti-Parkinson's disease drug for administering to a patient in need of anti-Parkinson's disease therapy.

en

Dosage form indicated for the management of abnormal posture, tremor and involuntary movement

5242357_US

5591736_US,5591737_US,5343375_US,5606318_US

A61K 9/0004

[ "A61K 9/26", "A61K 9/22", "A61K 9/00" ]

45,056

54,381,328

2008-01-08

39,641,625

N

Genes associated with schizophrenia are identified. Methods of screening small molecule compounds for use in treating schizophrenia are described.

en

GENES ASSOCIATED WITH SCHIZOPHRENIA

5223287_US

10679121_US,10679122_US,5838686_US

C12Q 1/6883,C12Q2600/136,C12Q2600/156,C12Q2600/16

[ "C12Q 1/68" ]

48,994

49,723,345

1973-03-02

19,815,125

Y

The invention relates to certain psychopharmacological peptides with the formula: A-L-Glu(X)-L-His-L-Phe-L-Arg(or L-Lys)-Y in which A represents:

en

PSYCHOPHARMACOLOGICALLY ACTIVE TETRA-, PENTA-, HEXA-, AND HEPTAPEPTIDES

20859138_

34926652_

A61K 38/00,C07K 14/695,C07K 14/6955

[ "A61K 38/00", "C07K 14/695" ]

39,264

554,298,997

2020-12-18

76,858,169

N

Disclosed herein include systems, methods, devices, and computer readable media for constructing a neural network by growing and self-organizing.

en

SELF ORGANIZATION OF NEUROMORPHIC MACHINE LEARNING ARCHITECTURES

5211760_US

79655245_US,79657723_US,79701923_US

G06N 3/049,G06N 3/08

[ "G06N 3/04", "G06N 3/08" ]

155,621

4,274,962

1987-10-07

36,926,794

Y

The present invention relates to novel compounds of the formula: (see above formula) useful in the treatment of epilepsy and other CNS disorders.

en

AMINO ACID DERIVATIVE ANTICONVULSANT

6318256_US

13350102_US,13350101_US

A61K 31/165,A61K 31/195,A61K 31/34,A61K 31/38,A61K 31/40,A61K 38/04,A61P 25/08,C07C 237/22,C07C 323/59,C07D 207/34,C07D 307/68,C07D 333/24

[ "C07C 237/22", "C07C 237/06", "C07D 333/24", "C07D 307/68", "C07D 307/66", "C07C 323/59", "C07D 207/34", "A61K 31/16", "C07D 207/327", "C07C 237/04", "A61K 31/341", "A61K 31/33", "A61K 31/34", "A61K 31/40", "A61K 31/165", "A61K 31/195", "A61K 31/38", "C07C 233/00", "A61K 31/381", "C07C 237/08", "A61K 38/00", "C07C 273/10", "A61K 38/04", "A61P 25/08" ]

3,738

48,425,351

1988-04-07

27,449,909

Y

Selective dopamine D1 receptor agonists for use in the treatment of primary degenerative dementia, depression, anxiety, obesity or schizophrenia.

en

Uses of dopamine receptor agonists

5243521_CH

6672201_CH,5444225_DE

A61K 31/00,A61K 31/40,A61K 31/475,A61K 31/48,A61P 3/04,A61P 25/18,A61P 25/24,A61P 25/26,A61P 25/28,A61P 43/00

[ "C07D 457/14", "A61K 31/475", "A61K 31/00", "A61P 25/26", "A61P 25/18", "A61P 25/24", "A61P 3/04", "A61K 45/00", "A61K 31/48", "A61P 25/28", "A61P 43/00" ]

37,180

48,793,823

1988-07-25

26,918,357

Y

Method of blocking 5HT without effect on alpha receptors with 1-loweralkyl-6-straight chain alkyl-8 beta -hydroxycycloalkyloxycarbonylergolines.

en

4-hydroxycyclohexyl 1-isopropyl-9,10-dihydro-lysergate for the treatment of migraine

5255150_US

5672952_US,6168678_US,5755752_US,5672949_US

A61K 31/48

[ "A61K 31/48" ]

37,772

549,449,450

2021-04-07

75,640,024

N

A method for treatment of viral infections, especially SARS-CoV-2 infections, said method comprising the administration of hydrolysable tannins.

en

HYDROLYSABLE TANNINS FOR USE IN MITIGATING ACUTE RESPIRATORY DISTRESS SYNDROME

57332079_US

13127287_US,43137885_US

A61K 9/2054,A61K 9/4866,A61K 31/366,A61K 31/4706,A61K 31/513,A61K 31/573,A61K 31/7004,A61K 31/7024,A61K 31/7048,A61K 31/706,A61K 36/185,A61K 36/36,A61K 36/47,A61K 36/53,A61K 36/81,A61K 36/87,A61P 11/00,A61P 31/14,A61P 37/04

[ "A61K 31/7048", "A61P 31/14", "A61K 31/366", "A61K 31/7024", "A61K 31/573", "A61K 31/4706", "A61K 31/513", "A61P 11/00", "A61K 31/706" ]

152,393

45,631,475

2001-09-24

22,886,745

Y

Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomicapplications.

en

HUMAN ION-EXCHANGER PROTEINS AND POLYNUCLEOTIDES ENCODING T HE SAME

13015564_US

37035729_,37028716_

A61K 38/00,C07K 14/705

[ "C12N 15/09", "C12N 1/21", "C12N 1/15", "C07K 14/705", "C12N 15/12", "A61K 38/00" ]

30,355

504,068,265

2016-05-17

56,008,637

N

The present principles proposes an invertible and low complexity inverse gamut mapper that preserves invariance of colors near the white point.

en

METHOD AND DEVICE FOR PROCESSING COLOR IMAGE DATA REPRESENTING COLORS OF A COLOR GAMUT

5371127_FR

6028554_FR,52532317_FR,54754172_FR

G09G 3/2003,G09G 5/02,G09G 5/10,G09G2340/06,H04N 1/6019,H04N 1/6058,H04N 19/186,H04N 19/85

[ "H04N 19/85", "H04N 19/186" ]

123,176

15,731,326

1993-05-07

25,468,285

Y

The invention relates to 5-(2-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-di hydro-2H-indol-2-one hydrochloride monohydrate.

en

Benzisothiazol-piperazinyl derivative and its use as neuroleptic

47609_US

828431_US

A61P 25/02,A61P 25/18,A61P 25/20,C07D 209/04,C07D 413/12,C07D 417/06,C07D 417/12

[ "A61K 31/47", "C07D 295/02", "C07D 263/54", "C07D 277/62", "A61K 31/427", "A61P 25/02", "C07D 417/14", "A61K 31/496", "C07D 215/38", "C07D 235/04", "C07D 209/04", "C07D 215/16", "A61P 25/20", "A61P 25/18", "C07D 417/12", "C07D 403/12", "A61K 31/495", "C07D 403/06", "C07D 249/18", "C07D 413/12" ]

12,523